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ABSTRACT

MACROMOLECULE LOADING ON PLGA PARTICLES THROUGH SURFACE
ADSORPTION

By
Yiwei Wang
August 2018

Thesis supervised by Wilson Meng

The advent of biotherapeutics have impacted the ways in which diseases are treated. In
many instances development of recombinant proteins and oligonucleotides into
therapeutics are slowed by poor stability of the candidate drugs. Progress has been made
in using polymeric particles as carriers of macromolecule drugs. Historically the method
is to encapsulate biological drugs into spherical polymeric matrices.

Owing to its

biocompatible and biodegradable nature, poly (d,l-lactic-co-glycolic acid) (PLGA) has
been used extensively in formulating biological drugs into nano- and micro-sized particles.
The development of PLGA biologic formulations, however, has been hampered by matrix
acidification; the hydrolysis of the polymer generates non-diffusive acid fragments by
which the interior pH can be driven to as low as 2, a condition unfavorable for proteins and
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oligonucleotides to remain intact. In addition, loading of proteins through encapsulation
can lead to substantial loss of activity because of homogenization or sonication-induced
denaturation. To circumvent these limitations yet still take advantage of the proven safety
of PLGA in humans, I proposed to load macromolecules onto the surface of PLGA particles
functionalized with biotin (“PLGA-biotin”).

The specific binding between avidin and biotin (or desthiobiotin) was employed to enable
surface adsorption. The pair has the strongest known non-covalent affinity, an interaction
that is relatively insensitive to temperature and pH. PLGA-biotin particles were prepared
by co-emulsifying the lipid DSPE-PEG-biotin with PLGA into a matrix. The tetravalent
feature of avidin was used to bridge biotinylated proteins or oligonucleotides onto PLGAbiotin particles. The hypothesis of this project is that solvent-accessible biotin molecules
are displayed on PLGA-biotin particles. The rationale for my hypothesis is that the coemulsification of the biotinylated lipid DSPE-PEG-biotin and the polymer matrix PLGA
has the potential to generate PLGA particles functionalized with biotin molecules
embedded on the surface. As a result, the interaction between biotin and avidin can be
utilized to load macromolecules onto the surface of these modified PLGA particles through
adsorption, circumventing the challenges to the stability and bioactivity of the biological
drugs caused by the encapsulation process and the acidic environment inside PLGA
particles during the degradation of the polymer matrix. Two specific aims were carried out.
In aim 1, the presence of biotin in PLGA-biotin particles was verified and the physical
attributes of the particles, namely particle size and zeta potential, were characterized.
Spectroscopic and biochemical studies indicated the presence of biotin on the particle
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surface. In aim 2, the amount of biotin accessible on PLGA-biotin particles was quantified.
Taken together, the data generated in this thesis support the notion that surface adsorption
is a general method for loading macromolecules onto PLGA particles. The work presented
is a step toward a new platform in formulating biotherapeutics.
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Chapter 1: Introduction

1.1. Biologics: Delivery Challenges

Biologics have revolutionized the treatment of diseases and attracted growing interests
among drug development scientists during the past two decades (Morrow, T. and L. H.
Felcone, et al. 2004). Whereas biologics used to be limited to peptides and natural proteins,
the range of therapies has since expanded to include recombinant antibodies, antisense
oligonucleotides, plasmid DNA, fusion proteins, and Crisper-Cas9 (Morrow, T. and L. H.
Felcone, et al. 2004). An important consideration in formulating a biological drug is the
need to protect and retain its structure and activity (Felcone, L. H. 2004), which can be
negatively impacted by production processes and physiological factors.

Since the early 1980s there have been continuing interests in formulating recombinant
proteins and nucleic acids for therapeutic purposes (Paulo, C. S., et al. 2011). The number
of clinical trials studying proteins, peptides and antisense oligonucleotides has steadily
increased for the past two decades. With their inherent high specificity and affinity,
recombinant proteins are believed to be capable of treating chronic diseases, cancers and
autoimmunity (Szlachcic, A., et al. 2011). As complex cellular pathways are being unveiled
at a rapid pace, endogenous protein partners in checkpoint mechanisms are selected to
become candidates for therapeutic agents.
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One major problem of protein drugs is that they tend to be unstable both in vitro and in
vivo. Thus, the applicability of proteins to work as effective therapeutics is restricted (Lin,
S. 2015). In the absence of stabilizers, many proteins aggregate and/or undergo chemical
degradation processes. The common causes of chemical instability are hydrolysis,
deamidation, isomerization, racemization, oxidation, disulfide exchange, dimerization, βelimination, and Maillard reaction (Jacob, S., et al. 2006). Their susceptibility to proteases
also poses challenges in protein production and purification, resulting in inadequate
concentration of protein drug in vivo to reach the targets (Jiskoot, W., et al. 2012). In
addition, protein drugs can be the targets of translational modifications and immune
responses under specific circumstances, which leads to reduced efficacy and possible
hypersensitivity (Jiskoot, W., et al. 2012).

1.2. Application of Particles in Biotherapeutics Delivery

A number of encapsulation approaches have been used to formulate protein drugs (Pisal,
D. S., et al. 2010). These include the use of micro-encapsulation to enable sustained release
of protein drug and subsequently reduce the required frequency of administration
(Gregoriadis, G., et al. 2005, Tan, M. L., et al. 2010). Among the materials and delivery
vehicles that are currently under investigation for the delivery of nucleic acid therapeutics
particle-mediated delivery, poly (lactic-co-glycolic acid) (PLGA) particles have
advantages such as the ease and speed of preparation, the stability of the nucleic acids in
preparation, the absence of viral antigens, and the ability to target different tissue depths
and areas (Danhier, F., et al. 2012).
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Poly (d,l-lactic-co-glycolic acid), or PLGA, one of the most successfully developed
biodegradable polymers, has been intensively investigated for fabricating delivery vehicles
for macromolecule drugs (Ye, M., et al. 2010, Pisal, D. S., et al. 2010). The PLGA particles
developed for protein and oligonucleotides formulations typically have diameters ranging
between 1 to 250 m , in most cases designed as injectable (Pisal, D. S., et al. 2010). The
rationale for using PLGA is partly due to its biodegradable nature, and that it is FDAapproved for use in humans for three decades. While many PLGA-based strategies have
been characterized in preclinical studies, challenges remain in ensuring therapeutic
concentration of the protein at the site of action without substantial adverse reaction. In
many cases particles infused intravenously are trapped in the monocytic-phagocytic system,
located primarily in the spleen and liver, but also in secondary lymphoid tissues (Furth, R.
1998, Trevaskis, N. L., et al. 2015). Nevertheless, PLGA remains an attractive polymer
because of its long safety record in the general population.

Degradation of PLGA microparticles typically occurs on the scale of weeks or months,
making such particles potentially viable carriers for sustained delivery of proteins and
oligonucleotides (van de Weert, M., et al. 2000). According to a study (Makadia, H. K. and
S. J. Siegel 2011) on the relationship between the degradation rate of PLGA and the
percentage of PGA in PLGA matrices, the degradation rate of PLGA increases as the
percentage of PGA increases from 25 to 50. Because of the chiral center in lactic acid, PLA
has a higher crystallinity than PGA and a lower permeability. PLA has a slow degradation
over several months, while PGA degrades over several weeks. Therefore, when the
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percentage of PGA increases, PLGA becomes more amorphous and more rapidly
biodegradable. Accordingly, PLGA with composition of PLA: PGA equals 50:50 has
demonstrated the fastest biodegradation rate of the polymers with near complete
degradation in 50–60 days (Figure 1-1). Because of this ideal degradation rate, PLGA50:50
is currently the most widely used type of PLA-PGA copolymer in particle preparation and
therefore is selected for preparing PLGA-Ni and PLGA-biotin particles in this project.

Figure 1-1. Degradation rate of PLGA with different ratios of PLA: PGA.

The biodegradation rate of PLGA is depending on not only the copolymer ratio but also
the molecular weight. Thus, the molecular weight and composition of PLGA can be
adjusted to change the chemical and physical properties of carriers and control the speed
of degradation as well as the rate of drug-release. Molecular weight has a direct relation
with the polymer chain size. Polymers having higher molecular weight have longer
polymer chains, which require more time to degrade than small polymer chains. Increasing
the molecular weight of PLGA polymers from 10 to 100 kDa, degradation rates ranging
from several weeks to several months were reported (Gentile, P., et al. 2014). Generally,
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the lower molecular weight PLGA nanocarriers/microcarriers degrade more quickly,
resulting in a quick pH decline. Considering the influence of rapid decrease in pH inside
PLGA particle on the macromolecules loaded, PLGA polymers with low molecular
weights are not frequently used for the delivery of biological drugs, especially those
requiring a sustained release.

In addition to formulation of proteins, the application of PLGA particles on gene therapy
has also attracted a great deal of attention in recent years. Gene therapy, i.e., the expression
in cells of genetic material with therapeutic activity, holds great promise for the treatment
of human diseases (Resende, R. R., et al. 2007). A delivery vehicle (vector), of either viral
or non-viral origin, must be used to carry the foreign gene into a cell. Viral vectors take
advantage of the facile integration of the gene of interest into the host and the high
probability of its long-term expression but are plagued by safety concerns (Auman, J. T.
2010). Non-viral vectors, although less efficient at introducing and maintaining foreign
gene expression, have the profound advantage of being non-pathogenic and nonimmunogenic (Thomas, M. and A. M. Klibanov 2003). PLGA particles are particularly
attractive for non-viral gene therapy (e.g., Tahara, K., et al. 2008).

1.3. Challenges in Encapsulating Biologics into PLGA Particles

A particular challenge in using PLGA particles for biotherapeutic delivery is to ensure the
payload retain the structure and biological activity (van de Weert, M., et al. 2000). It should
be noticed that the hydrolysis of PLGA generates acidic fragments including glycolic acid
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and lactic acid (Makadia, H. K. and S. J. Siegel 2011). Because PLGA is a bulk erosion
polymer, its degradation rate is slower than the water penetration rate (von Burkersroda,
F., et al. 2002). Therefore, the acidic fragments will be trapped inside the PLGA particle.

The accumulation of these acidic polymer fragments can decrease the pH in the matrix to
as low as pH 3 to pH 2 (Figure 1-2), which would facilitate the degradation of the polymer,
and also denature the encapsulated protein (Fu, K., et al. 2000, von Burkersroda, F., et al.
2002). Additionally, protein denaturation often occurs during microparticle preparation,
such as the homogenization and/or sonication steps, and at the interface of organic phase
and aqueous phase (Xiong Y.L. 1997). As a result, the loading efficiency of protein on
PLGA particles varies and can be very poor. To circumvent these challenges, I propose to
load proteins through surface adsorption onto a modified format of PLGA microparticles.

Figure 1-2. The pH change inside PLGA matrix caused by the accumulation of acidic
degradants.

The phenomenon of adsorption is essentially an attraction of adsorbate molecules to an
adsorbent surface. Adsorption processes can be classified as either physical adsorption (van
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der Waals adsorption) or chemisorption (activated adsorption) depending on the type of
forces between the adsorbate and the adsorbent.

The individuality of the adsorbate and the adsorbent are preserved in physical adsorption.
In contrast, chemisorption involves a transfer or sharing of electron, or breakage of the
adsorbate into atoms or radicals which are bound separately, forming chemical bonds
between the adsorbate and adsorbent. In this project, noncovalent chemical bonds are
utilized to enable chemisorption of biological drugs on the surface of PLGA-Ni or PLGAbiotin particles.

1.4. Ligands and Proteins Used for Surface Modification and Adsorption

1.4.1. Biotin

Biotin is a water-soluble B-vitamin, also called vitamin B7 and vitamin H or coenzyme R
(Ross, C., et al. 2014). As showed in Figure 1-3, it is composed of a ureido ring fused with
a tetrahydrothiophene ring. A valeric acid substituent is attached to the tetrahydrothiophene
ring, which can be derivatized in order to incorporate various reactive groups that facilitate
the addition of a biotin tag to other molecules. Biotin is present in small amounts in all
living cells, involved in the synthesis of fatty acids, isoleucine, and valine, and in
gluconeogenesis (Zempleni, J., et al. 2007). Studies have shown that biotin binds tightly to
the tetrameric protein avidin and its analogues (Table 1-1), including streptavidin and
neutravidin (Laitinen, O. H., et al. 2006).
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Table 1-1. Comparison of biotin-binding proteins.
Streptavidin

NeutrAvidin (from

Avidin

(recombinant)

Avidin)

Molecular weight (kDa)

67

53

60

Biotin-binding sites

4

4

4

Affinity for biotin (Kd)

~1.3 x 10 -15 M

~0.04 x 10 -15 M

~1.3 x 10 -15 M

Nonspecific binding

high

low

lowest

Because biotin is relatively small (244.3 Daltons), it can be conjugated to many proteins
or other molecules without significantly altering their biological activity (Chapman-Smith,
A. and J. E. Cronan, Jr. 1999). This process is called biotinylation. The highly specific
interaction of biotin with biotin-binding proteins makes it a useful tool in assays designed
to detect or target biological analytes.

Figure 1-3. The chemical structure of biotin.
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The normal biotin plasma level ranges from 400-1200 ng/L with daily fluctuations up to
100% (Trueb, R. M. 2016). If biotin is taken externally, excessive amounts are not absorbed
and excreted with the feces. By contrast, absorbed amounts of biotin which exceed the
storage capacity of the organism are eliminated in the urine. Shortly after an oral take up
of biotin, the the biotin concentration in the plasma increases several times, but after 24 h
the average value is reached again (Bonjour, J.P. 1984). Furthermore, most of the biotin in
human plasma is not bound to protein. Approximately 81% of biotin in plasma is free and
7% is reversibly bound (Mock, D. M. and M. I. Malik 1992).

1.4.2. Avidin

Avidin is a protein derived from avians and amphibians, which shows considerable binding
affinity for biotin (Korpela, J. 1984). The monomeric subunit of avidin consists of a highly
similar topology comprising an eight-stranded antiparallel-barrel (Meir, A., et al. 2012, see
Figure 1-4). Avidin and its analogues are homotetrameric proteins with four biotin-binding
sites, and their high affinity characteristics are closely dependent on their quaternary
assembly (Meir, A., et al. 2012). In its tetrameric form, avidin is estimated to be 66–69 kDa
in size with 10% of is molecular weight contributed by carbohydrate (Green, N. M. 1975).
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Figure 1-4. Structures of tetrameric egg white avidin. Monomers were shown in magenta,
blue, cyan, and orange. The biotin ligand is shown in black in the binding site of the cyan
monomer (for clarity). The Trp residue (shown in red) from an adjacent monomer (blue)
contributes to the high affinity of biotin binding and is indicated by an arrow.

Through co-emulsification with biotinylated lipid, PLGA particles can be functionalized
with biotin molecules on the surface to generate PLGA-biotin particles. In this project,
avidin-biotin and avidin-desthiobion interactions provide the foundation for PLGA-biotin
particles to load nucleic acid drugs such as antisense oligonucleotides. But it should be
pointed out that the adsorption of biotherapeutics on PLGA-biotin particles, in this case, is
not through direct interactions. Avidin works as an intermediate connecting PLGA-biotin
particles and desthiobiotinylated biotherapeutics.

1.4.3. Desthiobiotin

Desthiobiotin is a derivative of biotin that lacks a sulfur atom. The lower affinity of
desthiobiotin allows to break the desthiobiotin/avidin bound by displacement using biotin,
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which makes desthiobiotin a label of choice to create reporter molecules dedicated to both
detection and separation techniques (Hirsch, J. D., et al. 2002). Unlike biotinylated proteins,
desthiobiotinylated proteins and their interacting partners can be readily and specifically
eluted under mild conditions when captured on avidin by using a biotin elution buffer
(Hirsch, J. D., et al. 2002). The soft release characteristic of desthiobiotin minimizes the
isolation of naturally biotinylated molecules that can interfere with results and also
eliminates the use of harsh elution conditions which can disassociate complexes and/or
damage the target protein or cell (Levy, M. and A. D. Ellington 2008). This technique is
ideal when using native or recombinant proteins that are not expressed with a fusion tag
and when it is required to isolate captured proteins under native conditions such as targeting
intact cells or cell surface proteins (Kimple, M. E., et al. 2013).

Figure 1-5. Chemical structures of biotin and desthiobiotin.
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Chapter 2: Adsorption of Avidin on PLGA-biotin Particles for
Biomacromolecules Delivery

2.1. Introduction

The avidin-biotin interaction is one of the strongest non-covalent interaction (Kd = 10-15 M)
interactions in the nature (Chivers, C. E., et al. 2011). The non-covalent interaction is
characterized by a rapid on rate (Kon), and once formed, is unaffected by extremes of pH,
temperature, organic solvents and other denaturing agents (Gitlin, G., et al. 1987).
Therefore, the binding sites in avidin are stable and functional over a wide range of pH and
temperature. Moreover, avidin is also amenable to many chemical modifications with little
to no effect on function, making it useful for the detection and protein purification of
biotinylated molecules (Meir, A., et al. 2012, Green, N. M. and E. J. Toms, 1973). Because
of these useful features, there has been a growing interest in exploring the applications of
avidin-biotin interaction in biochemical assays, affinity purification, and drug delivery.
However, the carbohydrate content and basic pI (10-10.5) of avidin can result in a high
amount of nonspecific binding (Green, N. M., 1975). Thus, careful optimization of
blocking and proper design of biotinylated probes are required to obtain the best assay
results.

Since the biotin label is stable and small, it rarely interferes with the labeled molecules and
therefore enables the avidin-biotin interaction to be used in robust and highly sensitive
assays. The following Figure 2-1 demonstrates how the amino acid residues from the
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binding pocket in avidin surround and contact the biotin molecule during this interaction.
Because desthiobiotin lacks a sulfur atom, the binding formed between the sulfur atom in
biotin and the hydroxyl group in threonine (K. Stierand, M. Rarey 2010). Thus,
desthiobiotin binds less tightly to avidin than biotin (Kd=10-11 M) with avidin (Hirsch, J.
D., et al. 2002).

Figure 2-1. Amino acid residues surrounding and contacting biotin in the avidin binding
pocket.

In this project, the non-covalent interaction between avidin and biotin was employed to
deliver biological drugs (Figure 2-2). Particularly, the biotinylated lipid DSPE-PEG-biotin
was used to co-emulsify with PLGA and PVA to generate particles functionalized with
biotin molecules on the surface, i.e. PLGA-biotin particles. The ultimate goal for this
project is to deliver biologics that are conjugated with desthiobiotin. Since desthiobiotin
(DB) has a lower binding affinity, it can be displaced by biotin or other avidin-binding
reagents such as 4-hydroxyazobenzene-2-carboxylic acid (Verdoliva, A., et al. 2010).
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Consequently, the conjugated protein drug or other biologics will be released from PLGAbiotin particles and start to work in vitro or in vivo.

Figure 2-2. Deliver desthiobiotinylated macromolecules through PLGA-biotin particles
(DB is the abbreviation of desthiobiotin).

2.2. Materials and Methods

2.2.1. Materials

DSPE-PEG (2000) biotin (3016.81 Da) was purchased from Avanti. Poly (D, L-lactide-coglycolide) (PLGA, 50:50, IV 1.0 dl/g, 150000 g/mol, overall PDI 1.5-2.0) was purchased
from Polysciences, Inc. Avidin (egg white protein content, 92%), polyvinyl alcohol (PVA,
86-89% hydrolyzed, low molecular weight), Invitrogen NativePAGE 4-16% Bis-Tris gel
(1.0 mm x 10 well), Novex sharp protein standard, Pierce LAL chromogenic endotoxin
quantitation kit, dichloromethane (DCM, 99.9%), Tris base, D-(+)-trehalose dihydrate,
RPMI 1640 medium, ACK lysing buffer, endotoxin-free ultrapure water and HABA were
purchased from Thermo Fisher Scientific. Protein G human recombinant, His tag (His-pG)
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was purchased from ProSpec. Cy3-ASO-DB (1 µg/µl; 10740.9 Da) was purchased from
Integrated DNA Technologies through custom synthesis. Anti-DEC205 Ab (160000 Da,
0.5 mg/ml, 25 µg 50 µl in total) and Allophycocyanin (APC)-labeled anti-CD86 Ab (0.2
mg/ml, 25 µg in total) were purchased from Biolegend. Purified Rat Anti-Mouse
CD16/CD32 (Mouse BD Fc Block) (0.5 mg/ml, 0.1 mg 0.2 ml in total) was purchased from
BD Biosciences. Paraformaldehyde was purchased from Sigma-Aldrich.

2.2.2. PLGA-biotin Particle Preparation

PLGA-biotin particles were prepared using the method of double-emulsion solvent
evaporation. Specifically, DCM was used as the organic phase and 1% PVA aqueous
solution was selected as the water phase. The aqueous solution of 8 ml 1% PVA was
prepared by stirring with heating at 90 C overnight. DSPE-PEG (2000) biotin (Figure 23) is the biotinylated lipid used to attach biotin molecules onto the surface of PLGA
particles. Because biotin is hydrophilic, it will be oriented into the water phase, while the
hydrophobic chain in DSPE-PEG (2000) biotin will be incorporated into the PLGA matrix.
Prior to emulsification, 18 mg of PLGA50:50 were dissolved in 1.2 ml of DCM and
combined with 900 µl of 10 mg/ml DSPE-PEG (2000) biotin in DCM, followed by the
addition of 1% PVA aqueous solution to the organic phase. Homogenization was
performed at 25000 rpm for 5 min on ice. By magnetic stirring in hood for 3.5 h to
evaporate DCM, the residual of the organic solvent was removed. Particles were collected
through centrifugation and then washed twice with 5 ml of ultrapure water by centrifuging
at 15k rcf, 4 C for 20 min. To protect the freeze-dried material, 4 ml of 2% trehalose
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aqueous solution was used as the lyoprotectants (Bissoyi, A., et al. 2016) and particles were
re-suspended in this solution. Then, pre-freezing was performed by rotating the glassware
containing particle suspension in dry ice-acetone bath (Phipps, A., et al. 1968). After
overnight lyophilization, particles were collected and stored in a glass vial wrapped with
parafilm and foil, and then saved inside a desiccator at 4 C. The yield of this PLGA-biotin
particle preparation is 86 mg of white powder.

Figure 2-3. The chemical structure of DSPE-PEG-biotin.

2.2.3. PLGA-blank Particle Preparation

PLGA-blank particles were prepared to function as a proper control that can reveal the
effect of surface modification on PLGA particles. The method employed is also doubleemulsion solvent evaporation. Organic phase is composed of 45 mg PLGA50:50 dissolved
in 3 ml of DCM, while the water phase is 20 ml 1% PVA aqueous solution in ultrapure
water prepared by stirring with heating around 90 ºC overnight. Water phase was added to
organic phase prior to the homogenization at 25000 rpm for 5 min on ice. Residual DCM
was evaporated by magnetic stirring in hood for 4 h. Particles were then washed twice with
10 ml ultrapure water by centrifuging at 15k rcf, 4 ºC for 20 min. Then, particles were resuspended in 10 ml 2% trehalose aqueous solution. Particle suspension was pre-frozen in
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dry ice-acetone bath, followed by overnight lyophilization. Finally, completely dried
particles were collected and stored in a glass vial wrapped with parafilm and foil, and then
saved inside a desiccator at 4 C. After complete lyophilization, the yield of PLGA-blank
particle preparation is 197 mg of white powder.

2.2.4. PLGA-biotin Particle Characterization

2.2.4.1. Characterize Particle Size and Zeta Potential of PLGA-biotin Particle

The size and Zeta potential of PLGA-biotin particles were measured by the Malvern
Zetasizer Nano-S (Malvern Instruments, UK) using the method of DLS (Stetefeld, J., et al.
2016). Similar to the DLS measurement for PLGA-Ni particles, a series of PLGA-biotin
particle suspensions were prepared to find the most suitable concentration for DLS
measurements. First, 5 mg of PLGA-biotin particles were washed with 1ml of ultrapure
water to get rid of trehalose, followed by re-suspending in 1 ml of ultrapure water. Next,
this suspension was diluted 2X, 10X, 20X, 50X, and 100X to make particle suspensions
with different concentrations. Then, particle size was measured on different dilutions using
DLS. The concentration at which both the attenuation and number of runs are ideal is
considered to be the best concentration for the measurement. Accordingly, both particle
size and Zeta potential of PLGA-biotin particles were then measured at this concentration.

2.2.4.2. Determine the Endotoxin Level in PLGA-biotin Particles
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To evaluate the level of endotoxin contained in PLGA-biotin particles, endotoxin-free
water was used for all steps in the preparation of PLGA-biotin particles. The endotoxin
concentration of prepared PLGA-biotin particles was quantified using Limulus Amebocyte
Lysate (LAL) chromogenic endotoxin quantitation kit.

Determining endotoxin levels is important to assess the efficiency of endotoxin removal
methods and prevent endotoxic shock, inflammation and/or sepsis in tissue culture cells
and animals injected with formulations contaminated by endotoxin (Galanos, C. and M. A.
Freudenberg, 1993). To evaluate the level of endotoxin contained in PLGA-Ni particles we
prepared, endotoxin-free water was used for all steps in the preparation process of PLGANi particles. The endotoxin concentration of PLGA-Ni particles was quantified using LAL
chromogenic endotoxin quantitation kit via a chromogenic signal generated in the presence
of endotoxins. Briefly, the LAL enzymatic cascade is activated by endotoxin at pH 6.0 to
7.5 and the amount of activated enzyme present is measured by its ability to cleave a
chromogenic substrate at pH 8.0 to 9.0, where the color formation can be used to quantify
endotoxin (Lindsay, G. K., et al. 1989, Roslansky, P. F. and T. J. Novitsky, 1991).

According to the user guide of Pierce LAL chromogenic endotoxin quantitation kit, a small
volume of the sample (10 μl) is combined with LAL, and endotoxins in the sample activate
the proteolytic activity of Factor C. When the chromogenic substrate is added, the activated
protease catalyzes the cleavage of p-nitroalinine (pNA), resulting in yellow color that can
be quantitated by measuring the absorbance at 405 nm (A405) and extrapolating against a
standard curve. A standard curve was created using the E. coli endotoxin standard included
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with each kit to calculate endotoxin levels as low as 0.1 EU/ml, where one endotoxin
unit/ml (EU/ml) equals approximately 0.1 ng endotoxin/ml of solution.

By testing the endotoxin standard solutions, an endotoxin standard curve was established.
Then, PLGA-biotin suspensions were measured on a microplate absorbance reader at 405
nm within about 30 minutes. Finally, the endotoxin concentrations of the samples, in this
case PLGA-biotin suspensions, were calculated based on the linear regression equation
from the standard curve.

2.2.4.3. FTIR Analysis for PLGA-biotin Particles

Fourier-transform infrared spectroscopy (FTIR) is a technique used extensively for the
characterization of organic, polymeric, and in some cases, inorganic materials (Berthomieu,
C. and R. Hienerwadel 2009). Because FTIR test uses infrared light to scan samples and
produce different spectral fingerprints for different chemical structures, it is commonly
used to observe chemical properties (Kocak, A., et al. 2009).

Before FTIR analysis begins, the first step is to collect a background spectrum that can be
subtracted from the test spectra. This will ensure that the actual sample is all that is
analyzed (Brault, J. W. 1996). Then the samples are analyzed by fully-computerized FTIR
spectrometer. Three samples were tested in this experiment, namely, 5 mg of PLGA-biotin
particles, 5 mg of PLGA-blank particles, and 5 mg of biotin. PLGA-blank particles were
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included to eliminate the influence of PLGA and trehalose on the spectrum of PLGA-biotin,
which facilitates effective comparison between PLGA-biotin and biotin.

A Nexus 470 Fourier Transform Infrared (FTIR) spectrometer was used to analyze the
functional groups present at the surface of PLGA-biotin and PLGA-blank particles. Each
sample was analyzed under inert conditions with 256 scans and a 4 cm−1 resolution. After
each scanning, the FTIR spectrometer generates a profile in the form of an absorbance
spectra, which shows the unique chemical bonds and the molecular structure of the sample
material. To make the spectra in a form suitable for analysis, the absorbance peaks were
converted to transmittance and the baseline was corrected for each sample.

2.2.5. Loading of Proteins on PLGA-biotin Particles

2.2.5.1. Loading of Avidin on PLGA-biotin Particles

It is expected that the PLGA-biotin particles prepared using the approach described above
have the ability to bind avidin. To prove this, 5 mg of PLGA-biotin particles were washed
and re-suspended in 0.5 ml PBS. Then, 5 µg of avidin was added to the particle suspension.
To compare the function of biotin molecules and nickel atoms on the surface of PLGA
particles, 5 mg of PLGA-Ni particles were included and treated using the same procedure.
Three control groups were designed, namely, PLGA-biotin particle suspension without
avidin, PLGA-Ni particle suspension without avidin, and 10 µg/ml avidin solution in PBS.
All samples were incubated at room temperature for 1 h before the supernatants were
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collected by centrifuging at 13600 rcf, 4 C for 20 min. Pellets were re-suspended in 0.5
ml of PBS.

To identify the proteins contained in the supernatants and pellets, SDS-PAGE
electrophoresis was conducted, followed by silver staining.

2.2.5.2. Loading of His-pG on PLGA-biotin Particles

It is expected that the PLGA-Ni particles prepared as described above have specific binding
with His-pG. Conversely, PLGA-biotin particles should not show binding affinity for Histagged proteins. To prove this, 5 mg of PLGA-Ni particles were washed and re-suspended
in 0.5 ml pH 8 Tris buffer. Then, 3 µg of His-pG was added to the particle suspension. For
the purpose of comparing the surface properties, 5 mg of PLGA-biotin particles were
treated with the same procedure. There were also three control groups included, namely,
PLGA-biotin particle suspension without His-pG, PLGA-Ni particle suspension without
His-pG, and 10 mg/ml His-pG solution in PBS. All samples were incubated at room
temperature for 1 h before the supernatants were collected by centrifuging at 13600 rcf, 4
C for 20 min. Pellets were re-suspended in 0.5 ml of PBS solution.

The supernatants and pellets saved were then used to run SDS-PAGE electrophoresis to
identify the proteins contained by silver staining.
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2.2.6. Quantification of Biotin on the Surface of PLGA-biotin Particles
Using HABA/Avidin Assay

HABA (4-hydroxyazobenzene-2-carboxylic acid) is an avidin-binding dye that binds to
avidin to produce a yellow-orange colored complex which absorbs light at 500 nm (Green,
N. M. 1965). The following Figure 2-4 and Figure 2-5 show the structure of HABA and
the HABA molecule in the binding site of avidin, respectively (Livnah, O., et al. 1993).
The H-bonds are shown in thin dashed lines. Biotin, Thr35 and Phe72 (displayed in dashed
lines) from the avidin/biotin complex are superimposed to show the relative positions of
the two ligands and the key differences in the positions of Thr35 and Phe72 in the binding
sites of the complexes (Livnah, O., et al. 1993). It is demonstrated in Figure 2-5 that the
confirmation of the aromatic amino acids in avidin, including tyrosine, tryptophan and
phenylalanine, were changed. As a result, the complex of avidin and HABA absorbs light
at 500 nm.

Figure 2-4. The chemical structure of HABA.

Because of the lower affinity of HABA for avidin (Kd = 5.8x10-6 M), biotin can
stoichiometrically displace HABA from its interaction with avidin and subsequently
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decrease the absorption of HABA-avidin complex at 500 nm (A500) proportionately
(Verdoliva, A., et al. 2010). This change in A500 relates to the amount of biotin in the
sample and provides a basis for spectrophotometric determination of biotin levels in
biological samples (Green, N. M. 1965). HABA/avidin reagent, therefore, enables an
estimation of the mole-to-mole ratio of biotin to avidin. By this method, an unknown
amount of biotin present in a sample can be quickly evaluated by measuring the absorbance
of the HABA-avidin solution before and after addition of the biotin-containing sample. It
has been reported in many literatures that HABA can be used for detection, localization,
isolation, and purification by taking advantage of its interaction with avidin that results in
a red shift to 500 nm (Hofstetter, H., et al. 2000, Magnotti, R., et al. 1999, Moor, N., et al.
2007).

Figure 2-5. Stereoscopic view showing the amino acid residues involved in forming the
avidin/HABA complex.

HABA/avidin reagent is specific for chromogenic applications that depend upon
quantification of biotin (Green, N. M. 1965). To quantify the amount of biotin on the
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surface of PLGA-biotin particles, a suspension of PLGA-biotin particles is added to the
HABA/avidin solution, a mixture of HABA and avidin. The following assay is based on
the binding of the dye HABA to avidin and the ability of biotin molecules on PLGA-biotin
particles to displace the dye in proportions. By this method, the unknown amount of biotin
present on PLGA-biotin particles can be evaluated by measuring the absorbance of the
HABA-avidin solution before and after the addition of PLGA-biotin particle suspension.

Table 2-1. Compare biotin, desthiobiotin and HABA binding affinity for avidin.
Kd
10-15 M
10-11 M
5.8x10-6 M

Biotin
Desthiobiotin
HABA

2.2.6.1. Standard curve for the interaction between biotin and HABA/avidin

Prior to analyzing particle samples, a standard curve was established according to the user
guide of HABA from Thermo Scientific, in order to assess the dose-response relationship
between the concentration of biotin standards and the corresponding decrease in A500.
First, HABA solution was prepared by adding 24 mg HABA to 9.9 ml of ultrapure water
with 0.1 ml of 1 mol/l NaOH. If HABA does not completely dissolve, add another 0.1 ml
of 1N NaOH and filter solution before use. HABA solution was stored at 4 °C. Then, the
HABA/avidin solution was prepared. Specifically, 67 µl of 10 mg/ml avidin aqueous
solution was added to 40 µl of the HABA solution prepared, and was diluted by adding
1.93 ml PBS solution. The HABA/avidin solution can be stored at 4 °C for up to 2 weeks.
24

A series of biotin standard solutions were also prepared, including concentrations of 0.01
µg/µl, 0.02 µg/µl, 0.03 µg/µl, 0.04 µg/µl, 0.05 µg/µl, 0.06 µg/µl, 0.07 µg/µl, 0.08 µg/µl,
0.09 µg/µl, and 0.1 µg/µl. Biotin was dissolved in ultrapure water. Then, 150 µl of the
HABA/avidin solution was added to each microplate well. The wells were marked with the
concentration of biotin that was intended to add to the well after the first scan. Additionally,
150 µl of the HABA solution without avidin was also included to obtain the absorption of
HABA itself, which is considered as the background signal in the test. Then, the plate was
thoroughly mixed on an orbital shaker for 30 min. Plate reader was used to measure the
absorbance of the HABA/avidin solution in each well at 500 nm and the value was recorded
as “A500 of HABA/avidin solutions before biotin standards were added”. Then, 20 µl of
each biotin standard solution was added to a well containing the HABA/avidin solution.
For the control, 20 µl of ultrapure water was added instead, to incorporate the biotin
concentration of 0 µg/µl in the test. After mixing as described above for 2 h, the plate was
scanned for the second time at 500 nm and the result was recorded as “A500 of
HABA/avidin solutions after the incubation with biotin standards” once the value remains
constant for at least 15 seconds. If the value tested is ≤ 0.15, dilute sample and repeat assay.

2.2.6.2. HABA/Avidin Assay for PLGA-biotin Particles

PLGA-biotin particles were used in this experiment to replace HABA in the HABA/avidin
binding assay, for the purpose of quantifying the amount of biotin on PLGA-biotin particles
that is solvent-accessible. Similar to the procedure used in establishing the standard curve,
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HABA solution and the HABA/avidin solution were prepared first as described above.
Then, 10 mg of PLGA-biotin particles were wash 3 times with PBS solution and resuspended in 20 µl of PBS solution to prepare the PLGA-bioitin suspension. In order to
exclude the influence of other functional groups on the surface of PLGA-biotin particles,
PLGA-blank particles were included to demonstrate the differences between PLGA-blank
and PLGA-biotin. The suspension of PLGA-blank particles was prepared using the same
method. The control was also used in this test, where ultrapure water instead of particle
suspension was added after the first scan. Moreover, the HABA solution was added as the
blank, providing the background signal in the measurements.

For the first scan, 150 µl of the HABA/avidin solution was added to each microplate well.
The plate was thoroughly mixed on orbital shaker for 30 min. Plate reader was then used
to measure the absorbance of the HABA/avidin solution at 500 nm and the value was
recorded as “A500 of HABA/avidin solutions before particles were added”. Next, the
HABA/Avidin solution was pipetted from each well to an eppendorf tube and added with
20 µl of the PLGA-biotin/PLGA-blank particle suspension. For the control, 20 µl
of ultrapure water was added instead to compare the effect of particle suspension against
water, which contains 0 µg/µl of biotin. The eppendorf tubes were mixed on a shaker at
room temperature overnight, followed by centrifuging at 15k rcf, 4 ºC for 20 min. Then,
100 µl of each supernatant was pipetted to a microplate well. Finally, the plate was scanned
for the second time at 500 nm and the results were recorded as “A500 of HABA/avidin
solutions before after the incubation with particles” once the values remained constant for
at least 15 seconds.
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2.2.7. Loading of Antisense Oligonucleotides on PLGA-biotin Particles

Antisense oligonucleotides (ASO) are synthetic single stranded strings of nucleic acids that
can bind to RNA and thereby reduce or alter the expression of the target RNA (Goyal, N.
and P. Narayanaswami, 2018). They can not only reduce expression of mutant proteins by
breakdown of the targeted transcript, but also restore protein expression or modify proteins
through interference with pre-mRNA splicing. There has been a recent revival of interest
in the use of antisense oligonucleotides to treat diseases such as neurodegenerative
disorders using different approaches to prevent disease onset or halt disease progression
(Xue, X. Y., et al. 2018, Evers, M. M., et al. 2015). Table 2-2 shows the applications of
antisense oligonucleotide drugs in recent studies (Goyal, N. and P. Narayanaswami, 2018).

Table 2-2. Antisense oligonucleotide chemistry and properties.
Chemical
ASO generation

modification

Major representative

Nuclease

Target-binding

resistance

affinity

Yes

Poor

Yes

Strong

Phosphorothioate
First generation Phosphate Backbone

oligonucleotides
2'-O-methyl and 2'-O-

Second generation Sugar Modification methoxyethyl ASOs,
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Locked nucleic acids
(LNA)

Third generation

Phosphate, ribose

Peptide nucleic acids,

and nucleoside

Phosphorodiamidate

modifications

morpholino oligomers

Yes

Strong

Recent studies have shown that ASO is capable of down-regulating the expression of CD86
protein expression on pulmonary dendritic cells and macrophages (Liao, W., et al. 2017).
CD86 is a B7-family molecule that is expressed on the surface of pulmonary and thoracic
lymph node antigen-presenting cells and is able to deliver essential costimulatory signals
to prime naive T-cells upon allergen (Larche, M., et al. 1998). Thus, it is believed that
CD86 expression on pulmonary antigen-presenting cells plays a vital role in regulating
immune responses and the treatment with ASO may have utility in asthma and other
inflammatory lung conditions (Crosby, J. R., et al. 2007).

By combining with mRNA and subsequently disturbing protein translation, ASO is able to
reduce the expression of CD86 on the surface of target cells. In this project, ASO is
conjugated with Cy3, a dye that can be detected by fluorescence measurement (Mujumdar,
R. B., et al. 1993). With attachment of desthiobiotin, Cy3-ASO can be loaded onto avidin
through the interaction between desthiobiotin and avidin. Desthiobiotin is a biotin analogue
that binds less tightly (Kd = 10-11 M) to biotin-binding proteins and is easily displaced by
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biotin (Hirsch, J. D., et al. 2002). Although biotin has extremely high binding affinity
towards avidin (Kd = 10-15 M), desthiobiotin instead of biotin is utilized to bind avidin in
this experiment because the biotin/avidin interaction is essentially irreversible under
physiological conditions, which is disadvantage to its application (Chivers, C. E., et al.
2010). On the contrary, desthiobiotinylated molecules are easily eluted from the complex
in the presence of excess biotin.

On the other hand, avidin can also bind the biotin molecules on PLGA-biotin particles in
the mean time since there are four binding sites available on avidin. With proper molar
ratio in reaction, Cy3-ASO-desthiobiotin-avidin can be delivered by PLGA-biotin particles.
Therefore, PLGA-biotin particle is a promising carrier for ASO delivery. It should be
pointed out that desthiobiotinylated ASO is investigated in this project as an application
example of biological drugs that can be delivered via PLGA-biotin particles.

2.2.7.1. Standard Curve for the Fluorescence Intensity of Cy3-ASO-DB

To determine the loading efficiency of Cy3-ASO-desthiobiotin on PLGA-biotin particles,
the standard curve for fluorescence intensity from Cy3 versus the concentration of ASO
was established first. To begin with, a series of Cy3-ASO-desthiobiotin solutions with
different concentrations were prepared, including 0.025 µM, 0.05 µM, 0.1 µM, 0.2 µM,
0.4 µM, 0.8 µM, 1.6 µM, 3.2 µM, 6.35 µM, 12.7 µM. Considering the possible influence
of PLGA on fluorescence signals, the suspension of 5 mg PLGA-blank particles was then
added to each standard solution prior to the two-hour incubation at room temperature. Next,
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micro-plate reader was used to scan the fluorescence intensity from Cy3 (excitation: 550
nm/emission: 570 nm) in the Cy3-ASO-desthiobiotin standard solutions. Finally, the
standard curve was depicted using the readout from the fluorescence scan.

2.2.7.2. Loading Efficiency of Cy3-ASO-DB on PLGA-biotin Particles

In this experiment, PLGA-biotin particles were incubated with avidin-Cy3-ASOdesthiobiotin complex, followed by scanning the fluorescent from Cy3 in the pellets to
determine the loading efficiency of Cy3-ASO-desthiobiotin. First, 5 µl of 10 mg/ml avidin
aqueous solution was used to incubate with 15 µl of 1 µg/µl Cy3-ASO-desthiobiotin
aqueous solution for 30 min at room temperature. During this incubation, the avidin-Cy3ASO-desthiobiotin complex was formed. Next, the suspension of 5 mg PLGA-biotin
particles was added and incubated with the avidin-Cy3-ASO-desthiobiotin complex at
room temperature for 2 h with gentle shaking. Particles were centrifuged down and washed
with PBS solution to remove unspecific bindings. By re-suspending the pellets in 100 µl
of PBS solution, the sample for fluorescent scan was prepared. In the final step, microplate reader was used to scan the fluorescence intensity from Cy3 (excitation: 550
nm/emission: 570 nm) in each sample.

2.2.7.3. Sustained Release of Cy3-ASO-DB on PLGA-biotin Particles

Following the experiment of loading Cy3-ASO-DB to PLGA-biotin particles, pellets were
centrifuged down and re-suspended in 1 ml PBS. To monitor the release kinetics of Cy3-
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ASO-DB from PLGA-biotin, particle suspension was incubated at 37 ºC. At each
predetermined time point (1h, 2h, 3h, 4h, 5h on Day 1, and then once a day from Day 2 to
Day 16), centrifuge the pellets at 13500 rcf, 4 °C for 20 min and collect the supernatant
(950 µl) for fluorescence scan. Then, the eppendorf tube was replenished with another 950
µl PBS before resuming incubation at 37 ºC. By scanning the fluorescence intensity in the
supernatant saved at each time point from the dye Cy3, which has an excitation wavelength
at 550 nm and an emission wavelength at 570 nm, the amount of Cy3-ASO-DB released
into the supernatant sample was determined. Finally, the cumulative release of Cy3-ASODB in PBS was depicted based on the fluorescence scan for each sample.

2.2.8. Targeting Effect of Anti-DEC205 Ab Adsorbed and Delivered by
PLGA-biotin Particles

DEC205 is a type I cell surface protein expressed primarily by dendritic cells (DC). As a
phagocytosis receptor associated with CD8 T-cell responses, DEC205 plays an essential
role in mediating antigen uptake (Birkholz, K., et al. 2010). DEC205+ DCs mediate crosspresentation of antigen, resulting in modulation of CD8+ T-cell responses (Katakowski, J.
A., et al. 2016). Thus, DEC205 targeting represents a feasible method to deliver biological
drugs to DCs and regulate CD8+ T-cell activation. For instance, when ASO drug is
delivered by targeting DEC205+ DCs, the expression of CD86 on the surface of DEC205+
DCs will be decreased after the uptake of ASO and subsequently less CD8+ T-cells will be
activated and the inflammatory conditions will be relieved.
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To determine the targeting effect of anti-DEC205 antibody as well as the impact of antiDEC205 antibody on the accumulation of ASO in MHC class-II bone marrow cells in vitro,
Cy3-ASO-desthiobiotin

adsorbed

PLGA-biotin

particles

were

loaded

with

desthiobiotinylated anti-DEC205 antibody, followed by incubation with bone marrow cells.
Flow cytometry was utilized to analyze the uptake of the ASO drug in bone marrow cells
with and without the treatment of anti-DEC205 antibody, by detecting the fluorescence
intensity from Cy3 conjugated on the ASO drug.

First, bone marrow cells were harvested using the following procedure: 1). Euthanize mice
and spray the animal surface with 70 % ethanol. 2). Make an incision of the skin in the
mid-abdomen and remove the skin from the distal part including the skin covering the
lower extremities. 3). Cut off the muscles from the lower extremities using scissors and
carefully dislocate the acetabulum from the hip joint, while avoiding breaking the femur
head. 4). Remove the remaining muscles from the femur and tibia using a scalpel and
scissors and separate the femur from the tibia at the knee joint exercising care to not break
the bone ends. Place the bones in a Petri dish containing RPMI on ice. 5). Proceed to the
following steps in a hood. Take extra precaution to maintain strict sterile techniques to
avoid neutrophil activation. 6). Rinse each bone with 70% ethanol in a Petri dish, followed
by washing in sterile PBS within a Petri dish. 7). Inside a clean sterile Petri dish, cut off
the epiphyses of the bones and keep them aside. 8). Use a 25-gauge needle and a 10 ml
syringe filled with about 5 ml of RPMI (warm up to 37 ºC before using) to flush the bone
marrow cells from both ends of the bone shafts onto a 50 ml tube with a 70 µm cell strainer
attached. 9). Spin down the suspension at 400 x g for 5 min. Add 5 ml ACK lysing buffer
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on ice for 5 min. Then add 5 ml RPMI. Centrifuge at 400 x g for 5 min and remove the
supernatant. Wash remaining ACK with 5 ml of RPMI through centrifugation at 400xg for
5 min and remove the supernatant. 10). Wash cells twice with 5 ml sterile PBS, re-suspend
in 8 ml of RPMI and count. Keep the cells at 4 ºC. 11). Dispense 1 ml of cell suspension
into each well in a 24-well plate. Incubate the cells for 0.5 h at 37 ºC, 5% CO2.

Next, 3.8 µl of 1 µg/µl Cy3-ASO-dethiobiotin stock solution was incubated with 2.5 µl of
10 mg/ml avidin aqueous solution in an eppendorf tube for 30 min at room temperature.
Then, 11 µl of 0.5 mg/ml anti-DEC205 Ab stock solution was added to the avidin Cy3ASO-dethiobiotin complex and incubated for 30 min at room temperature. The mixture
was transferred to another eppendorf tube containing the suspension of 2.5 mg of washed
PLGA-biotin particles. Particles were incubated with ASO and anti-DEC205 Ab at room
temperature for 2 h to form Cy3-ASO-DB-avidin adsorbed PLGA-biotin particles, which
is referred to as “Cy3-ASO-DB-avidin-PB” in the following. The particle suspension was
then incubated with 1 ml of bone marrow cells harvested as described above (single cell
suspension, 1x106 cells/ml) in serum free media RPMI for 1 h at 37 °C, 5% CO2. The molar
ratio of anti-DEC205 Ab: Cy3-ASO-dethiobiotin: avidin: biotin on PLGA-biotin is 0.1: 1:
1: 10. To stimulate the expression of CD86, each well containing the bone marrow cell
suspension was added with 500 ng of lipopolysaccharides (LPS) in 1 ml of serum medium,
followed by overnight incubation at 37 ºC, 5% CO2.

On the next day, cells were pipetted out from each well and washed with 0.5 ml of FACS
buffer twice. Then, cells were re-suspend in 200 µl of FACS wash buffer (5% fetal bovine
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serum in PBS with 0.1% NaN3) and dispensed into eppendorf centrifuge tubes. The
following procedure was used to stain the bone marrow cells: 1). Split the 200 µl of cell
suspension in each tube to two tubes, resulting in 5x105 cells per tube. 2). For half of the
tubes, add 4.7 µl of 0.5 mg/ml Mouse BD Fc Block (Purified Rat Anti-Mouse CD16/CD32)
to block Fc receptors in flow cytometric analysis. Incubate on ice for 30 min. The following
steps are only conducted for these tubes. 3). Quantum satis each tube to 1 ml with FACS
wash buffer. Spin at 4 ºC, 10000 rcf for 5 min. Remove the supernatant after each wash
carefully. Finally, re-suspend each pellet with 100 µl FACS wash buffer. 4). Based on the
amount of cells in each well, add 3 µl Allophycocyanin (APC)-labeled anti-CD86 Ab to
each required sample (see Table 2-3 below). Incubate for 30 min on ice, wrapped with
aluminium foil. Allophycocyanin (APC) is a fluorescent dye. APC-labeled anti-mouse
CD86 antibody is used for cell staining. 5). Wash cells twice with 1 ml FACS wash
buffer. Spin at 4 ºC, 10000 rcf for 5 min. 6). Re-suspend cells in 200 μl FACS fixing buffer
(2% paraformaldehyde in PBS) and incubate for 10-15 min at room temperature. 7). Wash
cells 2-3 times with FACS wash buffer and re-suspend the pellets in 100 µl FACS wash
buffer. Ready for flow cytometric analysis. 8). Use the BD Accuri flow cytometer to
analyze each sample.
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Table 2-3. Sample order of bone marrow targeting experiment.

Name

Bone
marrow
cells

Cy3ASO-DBavidin-PB

avidinPB

antiDEC205
Ab

APC-labeled
anti-CD86
Ab

Control 1

+

-

-

-

-

Control 2

+

-

+

-

-

Control 3

+

-

+

-

+

Control 4

+

-

-

-

+

Control 5

+

+

-

-

-

Control 6

+

+

-

-

+

Exp 1

+

+

-

+

-

Exp 2

+

+

-

+

+

Comment
cells only
cells + particles
without ASO
stained cells
+particles without
ASO
single color control
for APC
single color control
for Cy3
not treated by antiDEC205 Ab
not stained by APC
treated by antiDEC205 Ab

Flow cytometry was used to measure the differences between bone marrow cells treated
and not treated with anti-DEC205 adsorbed PLGA-biotin particles. Fluorescence signal
from APC was detected in channel FL4-A; fluorescence from Cy3, the dye conjugated on
ASO, was in channel FL2-A. Thus, the fluorescence intensity in FL4-A indicates the
amount of cells expressed CD86 on the surface and subsequently interacted with APClabeled anti-mouse CD86 antibody. On the other hand, the fluorescence in FL2-A channel
suggests the accumulation of ASO in the bone marrow cells.

2.3. Results
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2.3.1. PLGA-biotin Particle Characterization

2.3.1.1. Characterize Particle Size and Zeta Potential of PLGA-biotin Particle

Dynamic light scattering (DLS) is commonly used to analyze microparticles and
nanoparticles. Because small particles in suspension undergo random thermal motion
known as Brownian motion, the light scattered by particles can imprint information about
their motion and size distribution profile. The best concentration of PLGA-biotin particle
suspension for DLS measurement was tested to be 2.5 mg/ml, at which both the attenuation
and number of runs showed an ideal value. Hence, the PLGA-biotin particle suspension
with 2 times dilution in PBS was selected as the appropriate particle suspension for
following DLS measurements including particle size and Zeta potential. The ideal

Figure 2-6. PLGA-biotin particles.

The average particle size detected is 717.83 nm (PDI 0.23) as showed in Figure 2-7,
indicating that the size of the PLGA-biotin particles prepared using the method described
above are microparticles with a moderately size distribution. Ideally, PLGA-biotin
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particles should show a polydispersity index (PDI) lower than 0.1. The PDI measured for
this batch of PLGA-biotin particles is slightly higher, but it is still in the acceptable range
(0.1-0.4). On the other hand, zeta potential values more electronegative than -30 mV
generally represent sufficient mutual repulsion to result in good stability. The average zeta
potential of PLGA-biotin particles is measured to be -21.4±0.153 mV (Figure 2-8), which
is lower than the ideal values but in the range of the threshold for delicate dispersions where
either coagulation or dispersion exists. To improve particle size distribution and zeta
potential, the process of preparation needs to be optimized in terms of the homogenization
time and rate, the amount of surfactant, and control of temperature throughout the process.

Figure 2-7. Particle size distribution of PLGA-biotin particles using DLS (the
concentration of PLGA-biotin is 2.5 mg/ml in pH 7 PBS solution with ionic strength of
162.7 mM).
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Figure 2-8. Zeta potential of PLGA-biotin particles using DLS (the concentration of
PLGA-biotin is 2.5 mg/ml in de-ionized water).

According to our previous study (Reger, N., et al. 2017), the average size of unmodified
PLGA particles was 426.8±11.7 nm with a PDI of 0.210±0.008, while the average zeta
potential of unmodified PLGA particles was −20.9±0.3 mV. Thus, the measurements of
PLGA-biotin showed that the attachment of biotin on PLGA particle has increased the
particle size and slightly decreased zeta potential, suggesting the difference between
PLGA-biotin and unmodified PLGA particles.

Table 2-4. The results of particle size and zeta potential measurements for PLGA-blank
and PLGA-biotin particles using DLS.
Particle Size (nm)

PDI

Zeta Potential (mV)

PLGA-blank

426.8

0.21

-20.9

PLGA-biotin

717.8

0.23

-21.4
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2.3.1.2. Determine the Endotoxin Level in PLGA-biotin Particles

Endotoxin standard curve was established (Figure 2-9) and the linear regression equation
was y = 3.2435x - 0.2669, R2=0.9724. The measurement showed that endotoxin
concentration of PLGA-biotin particles was 0.226 EU/mg or 1.01 EU/ml. According to the
manual of Pierce LAL Chromogenic Endotoxin Quantitation Kit, the correlation between
absorbance and endotoxin concentration is linear in the 0.1-1 EU/ml range. Therefore, the
endotoxin level of PLGA-biotin particles dosed in vivo could be acceptable as long as the
amount of PLGA-biotin particles is determined accordingly to ensure the endotoxin level
in dosage is below 5 EU/kg.

Figure 2-9. Standard curve for the determination of the endotoxin level in PLGA-biotin
particles.

2.3.1.3. FTIR Analysis for PLGA-biotin Particles
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In this project, FTIR was used to characterize the structure features of PLGA-biotin and to
verify the existence of biotin molecules on the surface of PLGA-biotin particles. Because
different types of bonds absorb infrared radiation of different wavelengths, the absorbance
peaks play an important role in determining whether the functional groups from biotin
appeared on PLGA-biotin. The FTIR spectra was then overlapped to provide more detailed
information about the functional groups in each sample.

Identification of the chemical features of PLGA and biotin were based on the structures in
Figure 2-10 and Figure 2-11. From the FTIR spectrum of PLGA-blank particles, peaks
indicating the functional groups found in PLGA were identified (Figure 2-12). The
strongest peak at 1761 cm-1 can be assigned to the stretching vibration of the carbonyl
group (C=O) in PLGA. The band at 802 cm-1 is assigned to the C-O-C deformation
vibration in the ester bond (R1-COO-R2) in PLGA. The band at 916 cm-1 most likely arises
from the C-H out-of-plane deformation vibration in the aliphatic polyester of PLGA.

Figure 2-10. The chemical structure of PLGA.
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Figure 2-11. The chemical structure of biotin.

Figure 2-12. FTIR spectrum of PLGA-blank and the peaks indicating the functional groups
in PLGA.

The FTIR spectrum of biotin is shown in Figure 2-13. The focus here is biotin-specific
spectra features. The strong peak at 3362 cm-1 can be attributed to N-H stretching vibration
in biotin, specifically the -OC-NH- structure. In addition, the bands at 754 cm-1 and 640
cm-1 are likely originated from N-H deformation vibration and N-H out-of-plane
deformation vibration respectively, supporting the presence of biotin. Additionally, there
are two peaks indicating the existence of C-N bond. One is at 1147 cm-1, corresponding to
the C-N stretching vibration in -C-NH-C- group; the other is at 1014 cm-1, which
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corresponds to stretching vibration of N-C-N. Evidence for the S-C bond in biotin can be
found in the PLGA-biotin spectrum: the band at 842 cm-1 is attributed to the stretching
vibration of S-C, which is one of the structural features of biotin.

Figure 2-13. FTIR spectrum of biotin and the peaks indicating the functional groups in
biotin.

The peaks in the FTIR spectrum of PLGA-biotin particles indicate structural features of
both PLGA and biotin (Figure 2-14). First, the strongest peak at 1759 cm-1 coincides with
the 1761 cm-1 peak in the FTIR spectrum of PLGA-blank particles. Thus, it is reasonable
to assign this peak to the stretching vibration of the carbonyl group (C=O) in PLGA.
Furthermore, the peak at 800 cm-1 is similar to the 802 cm-1 peak in the FTIR spectrum of
PLGA-blank particles. Both can be assigned to deformation vibration of C-O-C,
originating from the ester bond (R1-COO-R2) in PLGA. This comparison supports the
supposition that PLGA-biotin particles share common structural features with PLGA-blank
particles as expected.
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In addition, peaks indicating the presence of biotin can be found in the spectrum of PLGAbiotin particles. The strong peak at 990 cm-1 can be assigned to the stretching vibration of
C-N bond and the 690 cm-1 peak is due to the out-of-plane deformation vibration of N-H
bond in the biotin structure. The peak at 845 cm-1 resembles the peak at 842 cm-1 peak in
biotin spectrum of biotin, as both can be attributed to the stretching vibration of S-C bond.
These similar peaks validate the attachment of biotin on PLGA-biotin particles. In addition,
the 940 cm-1 band is likely due to the stretching vibration of the P-O bond, which is
presented in the structure linking the long alkane chain and PEG in DSPE-PEG-biotin
(Figure 2-3). The presence of this peak suggests the presence of the biotinylated lipid in
the PLGA-biotin sample.

Figure 2-14. FTIR spectrum of PLGA-biotin and the peaks indicating the functional groups
in PLGA and biotin.
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To highlight the differences in their chemical features, the FTIR spectra of PLGA-biotin,
PLGA-blank and biotin were overlapped. When overlapping the spectrum of PLGA-biotin
with that of biotin, several pairs of peaks appeared at similar wavelengths (Figure 2-15,
Figure 2-16). For example, the 990 cm-1 peak in PLGA-biotin and the 1014 cm-1 peak in
biotin are both related to the stretching vibration of C-N bond. The peak at 845 cm-1 in
PLGA-biotin and the peak at 842 cm-1 in biotin are assigned to the same chemical structure,
S-C bond, which features the chemical structure of biotin.

Figure 2-15. Overlap the FTIR spectra of PLGA-biotin and biotin using Origin.
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Figure 2-16. Zoomed in overlapped region of PLGA-biotin and biotin.

Such identical peaks are not found in the overlapped spectra of PLGA-blank particles and
biotin. In Figure 2-18, the two peaks mentioned above, 842 cm-1 and 1014 cm-1 in the
spectra of biotin were zoomed in. The former is formed by the stretching vibration of S-C
bond, and the latter is from the stretching vibration of C-N bond. In contrast to PLGAbiotin particles, the spectrum of PLGA-blank particles does not contain these peaks, which
indicate the structural features of biotin were not presented in PLGA-blank sample.
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Figure 2-17. Overlap the FTIR spectra of PLGA-blank and biotin using Origin.

Figure 2-18. Zoomed in overlapped region of PLGA-blank and biotin.
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The FTIR spectra of PLGA-biotin and PLGA-blank were also compared by overlapping
with each other. As showed in Figure 2-19 and Figure 2-20, similar bands appeared at the
wavelengths indicating the chemical structure of PLGA. More specifically, the peak at 800
cm-1 in PLGA-biotin and the peak at 802 cm-1 in PLGA-blank are both attributed to the CO-C deformation vibration in PLGA. In consistent with the previous analysis, peaks such
as the one from C-N stretching vibration at 990 cm-1 showed up again in the FTIR spectrum
of PLGA-biotin, suggesting that PLGA-biotin shares peaks with biotin in the mean time.

Figure 2-19. Overlap the FTIR spectra of PLGA-blank and PLGA-biotin using Origin.
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Figure 2-20. Zoomed in overlapped region of PLGA-blank and PLGA-biotin.

From the analysis above, it is observed that PLGA-biotin shares similar FTIR peaks with
both PLGA-blank and biotin (Table 2-4). But the common peaks of PLGA-biotin and
biotin did not appear in the spectrum of PLGA-blank. It should be noticed that the peak
from the deformation vibration of N-H bond was shifted from 640 cm-1 in biotin to 690
cm-1 in PLGA-biotin. One possible reason for this change is because the biotin molecules
were immobilized on the surface of PLGA-biotin particles and thereby absorb at a higher
frequency. In addition, the non-specific hydrogen binding between biotin molecules and
PVA, which has hydroxyl groups in the structure, on PLGA-biotin is another potential
cause for this energy shift. Thus, these results suggest that biotin was detected on PLGAbiotin particles but not on PLGA-blank particles.
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Table 2-5. Common peaks between PLGA-biotin and biotin/PLGA-blank.
PLGA-biotin

biotin

Functional Group

Comment

990 cm-1

1014 cm-1

C-N, N-C-N

C-N stretching vibration

845 cm-1

842 cm-1

S-C

S-C stretching vibration
N-H out-of-plane deformation

690 cm-1

640 cm-1

PLGA-biotin PLGA-blank

-NH-

vibration

Functional Group

Comment

1759 cm-1

1761 cm-1

C=O

C=O stretching vibration

800 cm-1

802 cm-1

R1-COO-R2

C-O-C deformation vibration

2.3.2. Loading of Proteins on PLGA-biotin Particles

2.3.2.1. Loading of Avidin on PLGA-biotin Particles

The capacity of PLGA-biotin to capture proteins were examined using gel electrophoresis.
According to the SDS-PAGE gel image (Figure 2-21), the sample of 3 µg/µl avidin
aqueous solution in lane 9 showed the strongest band intensity at 17 kDa, which should be
the molecular weight of each subunit in denatured avidin. Because the molecular weight of
avidin used is 68 kDa and there are 4 subunits, every subunit should be 17 kDa, which is
the same as the protein band identified in the result of SDS-PAGE electrophoresis.
Moreover, it has been reported in previous studies that under denaturing conditions, a
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spectrum of avidin subunit molecular weight could be ranging between 15-19 kDa (Bayer,
E. A., et al. 1986).

The 17 kDa band also appeared in lane 3 and lane 5, supernatants recovered after incubation
with avidin. This band did not appear in the pellets of PLGA-Ni after incubating with avidin
(lane 4). In contrast, the pellets of PLGA-biotin after incubating with avidin (lane 6)
showed this band at 17 kDa. This result demonstrated that avidin was adsorbed on PLGAbiotin particles but did not show specific binding to PLGA-Ni particles, suggesting that
biotin molecules were successfully attached onto the surface of PLGA-biotin particles.

Apart from the avidin solutions in lane 7 and lane 9, avidin (68 kDa) only appeared in the
supernatants of lanes 3 and 5), in which excess avidin remained undenatured. The reason
why this band was not found in the pellets of PLGA-biotin could due to the denaturation
of avidin adsorbed on PLGA-biotin particles during sample processing for electrophoresis.
The intensity of each protein band was quantified (Figure 2-21). It can be seen that lane 4
showed no significant band intensity at 17 kDa, while the pellets from incubating PLGAbiotin with avidin (lane 6) displayed a band intensity of 502 at 17 kDa. Additionally, by
comparing the band intensities in lane 6 and lane 7, Image J analysis suggested that roughly
1/3 of the protein added were captured by PLGA-biotin particles. These results indicate
that avidin only has specific binding with PLGA-biotin particles instead of PLGA-Ni
particles.
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Figure 2-21. Image J analysis for the SDS-PAGE result verifying the loading of avidin on
PLGA-biotin and PLGA-Ni particles. Sample order: lane 1-Control 1: PLGA-Ni
suspension, lane 2-Control 2: PLGA-biotin suspension, lane 3-supernatant from Exp 1:
PLGA-Ni suspension with avidin added, lane 4-pellets from Exp 1, lane 5- supernatant
from Exp 2: PLGA-biotin suspension with avidin added, lane 6-pellets from Exp 2, lane 7Control 3: 5 µg avidin in 0.5 ml PBS, lane 8-Blank: PBS, lane 9-3 µg/µl avidin stock
solution, lane mw: molecular weight marker.

The avidin stock solution was added in lane 9, which showed many proteins bands with a
higher molecular weight than avidin. One reason for this is that the avidin stock solution is
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92% pure with other egg white proteins included. Moreover, under the denaturing
condition in SDS-PAGE electrophoresis, avidin is likely to be denatured and the degradants
may have aggregations that leads to the upper proteins bands in the gel. However, the
strongest band at 17 kDa should come from avidin, since avidin is the main component in
this stock solution.

2.3.2.2. Loading of His-pG on PLGA-biotin Particles

The capacity of PLGA-Ni to capture proteins were also examined using gel electrophoresis.
In the SDS-PAGE gel image (Figure 2-22), the control His-pG (10 mg/ml PBS) in lane 7
showed the strongest band at 32 kDa, which is the close to the predicted molecular weight
of protein G. Because the amount of His-pG added was in excess, both the supernatants
collected after particles were incubated with His-pG in lanes 3 and 5 showed an identical
band around 32 kDa. However, the pellets collected upon centrifugation demonstrated
significant differences in proteins recovered. Following incubation with His-pG, the pellets
of PLGA-Ni were loaded in lane 4 and the pellets of PLGA-biotin were added to lane 6. It
can be observed that the band of His-pG at 32 kDa showed up in lane 4, but lane 6 did not
show this band or any protein bands. This result supports the claim that His-pG binds
specifically to PLGA-Ni particles but not PLGA-biotin particles.
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Figure 2-22. Image J analysis for the SDS-PAGE result verifying the loading of His-pG on
PLGA-biotin and PLGA-Ni particles. Sample order: lane 1-Control 1: PLGA-Ni
suspension, lane 2-Control 2: PLGA-biotin suspension, lane 3-supernatant from Exp 1:
PLGA-Ni suspension with His-pG added, lane 4- pellets from Exp 1, lane 5- supernatant
from Exp 2: PLGA-biotin suspension with His-pG added, lane 6-pellets from Exp 2, lane
7-Control: 10 mg/ml His-pG in PBS, lane 8-Blank: pH 8 Tris buffer.

2.3.3. Quantification of Biotin on the Surface of PLGA-biotin Particles
Using HABA/Avidin Assay
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2.3.3.1. Standard Curve for the Interaction between Biotin and HABA/Avidin

By scanning the absorbance of HABA solutions and the HABA/avidin complex, it was
observed that the absorbance of HABA, which was higher than 2 at 348 nm, was decreased
to around 1.6 after avidin was added (Figure 2-23). In contrast, the absorption at 500 nm
was increased from 0.09 in HABA solution to 0.3 in the HABA/avidin complex. Therefore,
these results suggest that the HABA/avidin complex has different absorbance properties
than HABA solutions due to the binding between HABA and avidin. This shift in
absorbance also provides the basis for relating the reduction in A500 to the displacement
of HABA from the HABA/avidin complex in HABA/avidin binding assay. Because biotin
can displace HABA and consequently decrease the absorption at 500 nm of the
HABA/avidin complex, HABA/avidin reagent was used in the binding assay to quantify
the amount of solvent-accessible biotin on the surface of PLGA-biotin particles.

Figure 2-23. Absorbance scan for HABA solutions and HABA/avidin complex.
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Specifically, a standard curve was depicted first by incubating biotin standards with the
HABA/avidin complex prior to the quantification of biotin using the samples of PLGAbiotin particle suspensions. All the wells showed similar absorption at 500 nm when biotin
standards were not added to the mixture of HABA solution and avidin solution. However,
distinct changes in A500 were observed in the scan result after incubating the
HABA/avidin complex with biotin standards.

Based on these results before and after biotin standards were added, the displacement of
HABA was almost completed when the concentration of biotin is higher than 0.08 µg/µl,
resulting in an absorption close to the background signal. Therefore, biotin concentrations
in the range from 0 to 0.08 µg/µl were selected to depict a standard curve, as showed in
Figure 2-24. According to this standard curve, the reaction between biotin and the
HABA/avidin complex is very sensitive. The absorption of the HABA/avidin complex at
500 nm starts to decrease significantly when the concentration of biotin solution exceeds
0.03 µg/µl.

Figure 2-24. Standard curve for HABA/avidin assay.
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Using this standard curve, the concentration of biotin in the sample of PLGA-biotin
suspension were calculated as the basis for quantifying the amounts of solvent-accessible
biotin on PLGA-biotin and the loading efficiency of the biotinylated lipid DSPE-PEGbiotin on PLGA-biotin.

2.3.3.2. HABA/Avidin Assay for PLGA-biotin Particles

HABA/avidin assay was then used to quantify solvent-accessible biotin on PLGA-biotin
particles. It should be pointed out that the initial absorbance values were obtained prior to
adding the particulate samples. These wells showed similar absorptions at 500 nm before
particles were added, which should be the A500 of the HABA/avidin solution (Figure 225). The wells marked with “HABA” contained only the HABA solution and showed a
weak absorption, which is considered as the background signal.

Figure 2-25. The results of the HABA/avidin binding assay before and after adding
particles. (a) A500 of HABA/avidin solutions before particles were added (one-way
ANOVA proved the four groups were significantly different with a p value 0.0001. Next,
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Turkey’s multiple comparison test was used to compare PLGA-blank with PLGA-biotin,
the p value0.005 indicates these two groups were similar prior to the incubation with
particles), (b) A500 of HABA/avidin solutions before after the incubation with particles
(one-way ANOVA proved the four groups were significantly different with a p value
0.0001. Next, Turkey’s multiple comparison test was used to compare PLGA-blank with
PLGA-biotin, the p value0.005 indicates these two groups are significantly different).

The absorbance (A500) was reduced after adding the particulate samples to the
HABA/avidin solution. Adding PLGA-biotin resulted in a decrease of 78%(1%), while
PLGA-blank reduced it by 31%(5%). According to statistical analysis using one-way
ANOVA and Turkey’s multiple comparison, wells added with PLGA-biotin particles
showed a more significant decrease in the absorption, indicating that the biotin molecules
on PLGA-biotin were able to interact with HABA/avidin and displace HABA molecules.
The slight change in PLGA-blank group, on the other hand, was likely caused by
nonspecific adsorption of HABA/avidin complex on PLGA-blank particles through
hydrogen bonding with the alcohol groups of the surfactant PVA.

Based on the measurements and results above, the amount of biotin on PLGA-biotin
particles was calculated. After the incubation with PLGA-biotin particles, the average
A500 was decreased by 0.116. According to the standard curve y = -2.4314x + 0.2832 (R2
= 0.9592), the concentration of biotin in the PLGA-biotin suspension is 0.069 µg/µl. Thus,
1.38 µg (0.0057 µmol) of biotin was attached on the surface of 10 mg PLGA-biotin
particles. This was extrapolated that at least 17.20 µg of DSPE-PEG-biotin (molecular
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weight: 3016.81 Da) were incorporated into PLGA-biotin particles. As described in the
PLGA-biotin particle preparation method, 9 mg of DSPE-PEG-biotin was added and 84
mg of PLGA-biotin particles were collected. Therefore, the maximum amount of DSPEPEG-biotin in 10 mg of PLGA-biotin particles was determined to be 107.1 µg. Based on
this calculation, 16.1% of the DSPE-PEG-biotin initially added were attached to the surface
of PLGA-biotin particles.

In a repeated experiment, similar results were observed. The average A500 was
significantly reduced to 0.125 when the HABA/avidin solution was incubated with PLGAbiotin particles, while the PLGA-blank particle suspension did not result in a considerable
reduction in the A500 of HABA/avidin complex (Figure 2-26). PLGA-biotin reduced A500
by 83%(3%), while PLGA-blank reduced it by 22%(7%). Again, this result suggests
that PLGA-biotin and PLGA-blank are significantly different and PLGA-biotin showed a
stronger ability of displacing HABA and reducing the absorption of the HABA/avidin
complex.

Figure 2-26. The results of the repeated HABA/avidin binding assay before and after
adding particles. (a) A500 of HABA/avidin solutions before particles were added(one-way
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ANOVA proved the four groups were significantly different with a p value 0.0001. Next,
Turkey’s multiple comparison test was used to compare PLGA-blank with PLGA-biotin,
the p value0.005 indicates these two groups were similar prior to the incubation with
particles), (b) A500 of HABA/avidin solutions before after the incubation with particles
(one-way ANOVA proved the four groups were significantly different with a p value
0.0001. Next, Turkey’s multiple comparison test was used to compare PLGA-blank with
PLGA-biotin, the p value0.005 indicates these two groups are significantly different).

Based on the standard curve mentioned above, the concentration of biotin in the PLGAbiotin suspension is calculated as 0.063 µg/µl this time. Following the calculation method
described in the first experiment, 14.6% of the DSPE-PEG-biotin initially added was
attached to the surface of PLGA-biotin particle.

By performing HABA/avidin binding assays, the biotin molecules on PLGA-biotin
particles were quantified and the loading efficiency of the biotinylipid DSPE-PEG (2000)
biotin on the surface of PLGA-biotin particles was calculated. For the PLGA-biotin
particles prepared in this project, the percentage of attached biotin in the total amount added
is around 15.4%. This loading efficiency calculated only relates to the amount of the
biotinylated lipid that was finally attached onto the surface, but maybe a lot biotin
molecules were also incorporated into PLGA-biotin particles, just not exposed on the
surface. Thus, a possible way for improving the loading efficiency is to optimize the
hydrophobic chain of the biotinylated lipid to achieve a more specific and more effective
interaction with the polymer matrix during the particle preparation process. Specifically,
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the possible approaches for the optimization of the hydrophobic chain may include
modifications such as increasing the chain length and adding hydroxyl groups onto the
chain. The former can enhance the hydrophobicity of the chain, making it more likely to
be intertwined with the polymer matrix. The latter will enable more non-specific hydrogen
binding between the chain and PLGA, but too many hydroxyl groups can also decrease the
hydrophobicity. Thus, it is necessary to design and conduct experiments in the future to
figure out the optimal length of the chain and most suitable modifications on functional
groups including the number of hydroxyl groups added to the chain.

2.3.4. Loading of Antisense Oligonucleotides on PLGA-biotin Particles

2.3.4.1. Standard Curve for the Fluorescence Intensity of Cy3-ASO-DB

The ASO drug Cy3-ASO-DB was loaded on PLGA-biotin as an application example of
biological drugs that can be delivered by PLGA-biotin particles. In order to quantify the
loading efficiency of Cy3-ASO-DB, the fluorescence intensity of the conjugated dye Cy3
on Cy3-ASO-DB was measured. Thus, based on the standard curve reflecting the
relationship between the fluorescence intensity and the concentration of Cy3, the
concentration of Cy3-ASO-DB can be determined.

First, from the results of fluorescence intensity measurements, a standard curve was
depicted as showed in Figure 2-27. The corresponding linear equation is y = 3562.5x +
691.85 (R2 = 0.9938). According to this standard curve, the concentration of Cy3-ASO-DB
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in the sample of PLGA-biotin suspension can be calculated. Afterwards, the loading
efficiency of the destiobiotinylated ASO drug on PLGA-biotin can also be quantified.

Fluorescence Intensity

Standard Curve
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y = 3562.5x + 691.85
R² = 0.9938
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Cy3‐ASO‐desthiobiotin concentration (µM)

Figure 2-27. Standard curve for the fluorescence intensity of Cy3-ASO-desthiobiotin with
PLGA particles added.

2.3.4.2. Loading Efficiency of Cy3-ASO-DB on PLGA-biotin Particles

Three replicates were included. On average, the samples showed a fluorescence intensity
of 33473. According to the standard curve y = 3562.5x + 691.85 (R2=0.9938), the average
concentration of Cy3-ASO-desthiobiotin in the samples is 9.2 µM. Based on this result, the
amount of Cy3-ASO-desthiobiotin in each sample was calculated to be 0.00092 µmol on
average. Since the total amount of Cy3-ASO-desthiobiotin initially added was 0.001397
µmol, the loading efficiency of Cy3-ASO-desthiobiotin turns out to be 65.87% based on
this test.
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2.3.4.3. Sustained Release of Cy3-ASO-DB on PLGA-biotin Particles

From the fluorescence intensity scans, the concentration of Cy3-ASO-DB in each release
sample was calculated and subsequently the cumulative amount of Cy3-ASO-DB released
into the release medium was also determined. Finally, the cumulative release of Cy3-ASODB was depicted in Figure 2-28. It is demonstrated in this release profile that when
adsorbed on PLGA-biotin, Cy3-ASO-DB showed a burst release, followed by a slow
release. In addition, 38.7% of the ASO drug was released into the supernatant after the first
two weeks.

Figure 2-28. The cumulative release of Cy3-ASO-DB from Day 1-Day 16 in PBS at 37 C
(n=3, the excitation/emission wavelength of Cy3 is 550 nm/570 nm).

The initial phase of the release (< 5 h) was likely due to dissociation of Cy3-ASO-DB nonspecifically adsorbed on PLGA-biotin particles; the phosphate backbone and bases form
hydrogen bonding with the hydroxyl groups in PVA on the surface. There could be two
driving forces for the avidin-bound Cy3-ASO-DB drug to be released. First, the
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concentration gradient in the release medium drives Cy3-ASO-DB to be dissociated from
its interaction with avidin on PLGA-biotin. Second, the degradation of the PLGA matrix
resulted in the release of Cy3-ASO-DB in a delayed fashion after ~20 days. Since the
dissociation constant of desthiobiotin-avidin interaction is small (Kd = 10-11 M), a high
percentage of Cy3-ASO-DB was not released until the PLGA matrix in PLGA-biotin
particle was degraded. But according to the study on the degradation of PLGA polymers
(Figure 1-1), the PLGA50:50 polymer matrix would not be degraded in the first two weeks.
Thus, the slow release phase in Figure 2-28 should be mainly from the Cy3-ASO-DB
released after the dissociation of desthiobiotin from avidin, which is also demonstrated as
Phase 2 in the release scheme (Figure 2-29). If the release study was prolonged, a third
phase (Phase 3 in Figure 2-29) driven mainly by the degradation of PLGA50:50 polymer
matrix would appear, where the remaining Cy3-ASO-DB would be released from PLGAbiotin.

Figure 2-29. Scheme for the proposed release mechanisms of desthiobiotinylated drug from
PLGA-biotin particles (for each release phase, there is one dominant release mechanism).

Under physiological conditions, the endogenous biotin molecules will displace
desthiobiotin from avidin and facilitate the release of Cy3-ASO-DB from PLGA-biotin.
The normal concentration of biotin in plasma ranges from 400-1200 ng/L (Trueb, R. M.
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2016), with approximately 81% of biotin in the free form. Thus, it is possible that the
adsorbed ASO drug will be displaced by biotin in vivo, preceding the dissociation of
desthiobiotin from avidin.

2.3.5. Targeting Effect of Anti-DEC205 Ab Adsorbed and Delivered by
PLGA-biotin Particles

Anti-DEC205 antibody is believed to be capable of targeting DEC205 molecules expressed
on bone marrow cells. Therefore, when anti-DEC205 antibody is adsorbed on PLGA-biotin
particles, the biological drug delivered by PLGA-biotin has the potential to achieve a
higher uptake by bone marrow cells. To evaluate the targeting effect of anti-DEC205
antibody and its impact on the accumulation of the ASO drug in bone marrow cells, the
fluorescence intensity from Cy3 in bone marrow cells was measured by flow cytometry
analysis, with and without anti-DEC205 antibody loaded onto PLGA-biotin particles.

For bone marrow cells in Control 1 that were not stained and not treated by Cy3-ASO-DBavidin-PB, more than 96% of the cells were showed as double negative in Figure 2-30. No
significant fluorescence signal was observed from the fluorescent dye APC or Cy3.
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Figure 2-30. The percentage of cells from Control 1 that showed fluorescence in FL2-A
and FL4-A.

In Control 2, cells were only incubated with PLGA particles that were not loaded with Cy3ASO-desthiobiotin. No staining was conducted using APC labeled antibody. However,
about 7.7% of the cells showed fluorescence in FL4-A, suggesting that this signal could
come from the background (Figure 2-31). No significant fluorescence signal was detected
from Cy3 in channel FL2-A.

Figure 2-31. The percentage of cells from Control 2 that showed fluorescence in FL2-A
and FL4-A.
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Bone marrow cells were stained and incubated with PLGA particles in Control 3, but the
particles were not treated with Cy3-ASO-dethiobiotin. Around 7.5% of the cells showed
fluorescence in FL4-A (Figure 2-32), which is close to the background measured in Control
2. The reasons for this result might be that the bone marrow cells were not completely
stained or the cells did not express many CD86 molecules in the first place. In channel
FL2-A, still no significant fluorescence signal was observed from Cy3.

Figure 2-32. The percentage of cells from Control 3 that showed fluorescence in FL2-A
and FL4-A.

As showed in Figure 2-33, when the cells were only stained with APC anti-mouse CD86
Ab, only 1% of the cells showed fluorescence from APC and no significant fluorescence
signal was detected from Cy3 in FL2-A. Again, this weak fluorescence signal suggests that
marrow cells were not completely stained or the cells did not express a significant amount
of CD86.
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Figure 2-33. The percentage of cells from Control 4 that showed fluorescence in FL2-A
and FL4-A.

In Control 5, bone marrow cells were only incubated with ASO-loaded particles, without
APC staining or the treatment of anti-DEC205 Ab. In the result (Figure 2-34), about 25%
of the cells showed fluorescence signal from Cy3, indicating that these cells were able to
uptake ASO. But around 19% of the cells were showed as positive in FL4-A channel even
though they were not stained with APC. It is possible that the signal from Cy3 influenced
channel FL4-A. However, there were still roughly 9% cells that are negative in FL4-A
showed significant fluorescence from Cy3 in FL2-A. This result is used later to assess the
effect of anti-DEC205 antibody on the uptake of ASO.
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Figure 2-34. The percentage of cells from Control 5 that showed fluorescence in FL2-A
and FL4-A.

Cells from Control 6 were included in measurements A05 and A07 (Figure 2-35). These
bone marrow cells were stained with APC and incubated with ASO-loaded particles, but
anti-DEC205 Ab was not added. About 14% of these cells were detected as double positive,
suggesting their ability of taking up Cy3-conjugated ASO. Whether ASO can reduce the
expression of CD 86 is later determined by comparing this result with the percentage of
double-positive cells in Exp. 2.
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Figure 2-35. The percentage of cells from Control 6 that showed fluorescence in FL2-A
and FL4-A.

In Exp. 1, cells were incubated with anti-DEC205 Ab and particles adsorbed with ASOCy3, but APC anti-mouse CD86 Ab was not used for staining. As showed in Figure 2-36,
about 60% of the cells had fluorescence in FL2-A, indicating that they took up ASO and
were labeled by Cy3. But around 20% of the cells were detected as positive in FL4-A
channel even though they were not stained. This percentage can be used as a background
of APC in analyzing Exp. 2.
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Figure 2-36. The percentage of cells from Exp. 1 that showed fluorescence in FL2-A and
FL4-A.

Bone marrow cells were stained by APC and incubated with both anti-DEC205 Ab and
ASO-Cy3 adsorbed PLGA-biotin particles in Exp. 2. In Figure 2-37, near 55% cells had
fluorescence from Cy3, but only around 16% of the cells were double positive. Comparing
with the percentage of double-positive cells in Control 6, i.e. 14%, there is no significant
decrease proving the expected effect of ASO on the expression CD86 in bone marrow cells.
However, it is noticeable that the cells showed fluorescence signal from Cy3 increased
significantly from 25% in Control 5 and 19% in Control 6 to 55% in Exp. 2. Thus, antiDEC205 still showed an impact on the uptake of ASO in bone marrow cells.
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Figure 2-37. The percentage of cells from Exp. 2 that showed fluorescence in FL2-A and
FL4-A.

To assess the effect of anti-DEC205 Ab on the uptake of Cy3-conjugated ASO, the
fluorescence from Cy3 in FL2-A was corrected by removing the influence of FL-4 in
Figure 2-38, Figure 2-39 and Figure 2-40. When there were only cells (Figure 2-38), no
fluorescence signal was detected in FL2-A. But after incubating with ASO-loaded particles,
more than 55% of the cells were positive in FL2-A channel without the treatment of antiDEC205 antibody (Figure 2-39). However, after loading anti-DEC205 antibody on PLGAbiotin, over 90% cells incubated with Cy3-ASO-DB adsorbed particles showed positive
fluorescence signals from Cy3 in FL2-A (Figure 2-40). This significant increase in the
percentage of cells positive in fluorescence channel of Cy3 suggests that anti-DEC205
antibody facilitates the uptake of the ASO drug in bone marrow cells.
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Figure 2-38. The percentage of cells from Control 1 that showed fluorescence in FL2-A
with color correction.

Figure 2-39. The percentage of cells from Control 5 that showed fluorescence in FL2-A
with color correction.
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Figure 2-40. The percentage of cells from Exp. 1 that showed fluorescence in FL2-A with
color correction.

Chapter 3: Conclusion, Discussion and Future Work on PLGA
Particles

3.1. Conclusion and Discussion

From what has been discussed above, we can draw a conclusion that by co-emulsifying the
biotinylated lipid DSPE-PEG (2000) biotin with the polymer matrix PLGA50:50 during the
preparation of PLGA particles, a novel particle, PLGA-biotin, was prepared. Using the
method of double-emulsion solvent evaporation, PLGA particles were finally
functionalized with biotin molecules on the surface. In this project, PLGA-biotin particles
have demonstrated significantly different particle properties against PLGA-blank particles,
which could be taken advantage of in delivering biological drugs.
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PLGA-biotin particles have particle sizes in the range of microparticles, with Zeta potential
in the range of the stability threshold for colloidal suspensions. The endotoxin levels in
PLGA-biotin is in the acceptable range for in vivo studies. The result from SDS-PAGE
electrophoresis proves the identity of proteins adsorbed on PLGA-biotin particles,
indicating that PLGA-biotin particles only have binding affinity for avidin and its
analogues. By performing the HABA/avidin binding assay, the amount of solventaccessible biotin on the surface of PLGA-biotin was calculated to be 15.4% of the initially
added biotinylated lipid. FTIR analysis also proved the existence of biotin molecules on
the surface of PLGA-biotin particles.

PLGA-biotin particle is specific to the proteins that can be adsorbed directly onto its
surface. Since the binding is based on the interaction between biotin and avidin, avidin
plays a bridging role in loading biological macromolecules onto PLGA-biotin particles.
The loading of all the macromolecules on PLGA-biotin in this project is through
chemisorption based on the chemical interaction between biotin and avidin. For example,
desthiobiotinylated biological drugs need to bind to avidin first, and then the resulting
complex interacts with PLGA-biotin if not all the binding sites in avidin are occupied.
Therefore, the molar ratio used for the reaction must be properly designed. For instance,
with the molar ratio of Cy3-ASO-dethiobiotin: avidin: biotin on PLGA-biotin equals 1: 2:
10, the loading efficiency of Cy3-ASO-desthiobiotin on PLGA-biotin particles was
measured to be 65.87%. In the bone marrow experiment, PLGA-biotin particles showed a
significantly higher uptake of Cy3-conjugated ASO when loaded with anti-DEC205
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antibody. However, the mechanism of introducing the oligonucleotides into cells by
PLGA-biotin particles remains as an unresolved issue.

For research in the future, it is also necessary to continue improving the efficiency of
loading desthiobiotinylated biologics onto PLGA-biotin particles. By optimizing the
structure of the hydrophobic chain in the biotinylated lipid, it is possible to achieve a more
effective interaction with PLGA matrix and increase the percentage of solvent-accessible
biotin on PLGA-biotin.

3.2. Adsorption of His-tagged Proteins on PLGA-Ni Particles for
Biotherapeutics Delivery

The previous study in our lab has prepared a PLGA particle functionalized with nickel
atoms on the surface, i.e., PLGA-Ni (Reger, N., et al. 2017). In order to compare the
properties of PLGA-Ni and PLGA-biotin in the delivery of biological drugs, the adsorption
of His-tagged proteins on PLGA-Ni particles was also studied in this project.

The interaction between nickel-nitrilotriacetic acid (Ni2+–NTA) matrix and polyhistidine
tag was employed in this project to enable the adsorption of proteins on PLGA-Ni particles,
which is adopted as the approach to deliver biologic drugs circumventing the potential
protein degradations during encapsulation. As demonstrated in Figure 3-1, the nickel atoms
in the Ni2+–NTA matrix can interact with the lone pairs on the imidazole rings in
polyhistidine tags (Bornhorst, J. A. and J. J. Falke, 2000). Most proteins with one His tag
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dissociate rapidly from the Ni2+–NTA surface, and the Kd for the interaction between His
tag and Ni2+–NTA was estimated to be about 10-6 M at neutral pH (Nieba, L., et al. 1997).
Based on this mechanism, recombinant proteins with polyhistidine tags can be loaded onto
PLGA particles if the particle surface is functionalized with Ni2+–NTA.

Figure 3-1. Interaction between Ni2+–NTA and polyhistidine tag.

Previous studies done by our group have shown that Ni2+–NTA can be localized on PLGA
particles by incorporating the metal chelating lipid in the organic phase using the solvent
evaporation method (Kovacs, J. R., et al. 2009). In this project, the metal chelating lipid
DOGS-NTA-Ni was used in the organic phase when preparing PLGA-Ni particles.
Through interweaving with the PLGA matrix, DOGS-NTA-Ni can be incorporated into
PLGA particles and consequently generate particles with nickel atoms on the surface. The
recombinant His-tagged protein G (HpG), a 21.6 kDa globular originated from
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Staphylococcal bacteria, will be utilized as the model protein drug. Other his-tagged
proteins, such as His-tagged green fluorescent protein (His-GFP) and His-tagged
transforming growth factor beta (His-TGFb), are also used to illustrate the interaction
between His-tag and nickel. In future studies, the ultimate goal is to utilize PLGA-Ni
particles (Figure 3-2) to deliver transforming growth factor beta-1 (TGF-1) in animal
models to suppress inflammation.

Figure 3-2. Deliver His-TGF-beta through PLGA-Ni particles.

3.2.1. Introduction

3.2.1.1. Nickel

Nickel is a silvery-white metal and also a chemical element with symbol Ni and atomic
number 28. People can be exposed to nickel by inhalation, ingestion, and contact with skin
or eye. However, nickel is immediately dangerous to life and health at 10 mg/m3 and the
lowest-observed-adverse-effects level (LOAEL) of Ni is 50 mg/kg/day determined in
human, according to Center for Disease Control (CDC)-NIOSH pocket guide to chemical
hazards for nickel metal and other compounds (CDC, ATSDR/U. S. 1988).
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The nickel atoms can be used to bind the hexahistidine motif, which is commonly referred
as "His tag", through chelation. This reversible interaction is estimated to have binding
affinities (Kd) between 10-5 to 10-7 M at neutral pH, an intermediate range that allows
loading and release of His-tagged proteins (Nieba, L., et al. 1997). This coordination
interaction has been used in affinity purification of genetically modified proteins, detecting
protein-protein interaction in binding assays and developing fluorescent tags for protein
migration (Kim, S. H., et al. 2007, Zhao, C., et al. 2010).

3.2.1.2. His-tagged Protein

One of the most commonly used fusion tags for recombinant protein expression and
purification is the His tag, which contains six or more consecutive histidine residues. Histagged proteins are recombinant proteins commonly expressed with a His-tag at the N or
C terminus of the polypeptide (Waugh, D.S., 2005). In contrast to other affinity tags, due
to its small size (0.84 kDa in the case of a hexahistidine tag) and the fact that it is uncharged
at physiological pH, the His tag typically does not affect folding in most cases does not
alter the activity of the fusion protein (Carson, M., et al. 2007). It has a low immunogenicity
and is compatible with most downstream applications.

Since the affinity of the His tag toward the Ni-NTA depends only on its primary structure,
His-tagged proteins can be purified under native or denaturing conditions (Hochuli, E., et
al. 1987). For instance, His-tagged proteins can be purified by a single-step affinity
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chromatography, namely immobilized metal ion affinity chromatography (IMAC), which
is commercially available in different kinds of formats, Ni-NTA matrices being the most
widely used (Spriestersbach, A., 2015). Purification of His-tagged proteins by IMAC is
based on the affinity of histidine residues for immobilized metal ions (e.g., Ni2+ or Cu2+).
The metal ions are immobilized on chromatographic matrices by a chelating ligand, most
commonly nitrilotriacetic acid (NTA) or iminodiacetic acid (IDA). While IDA has only
three metal-chelating sites, NTA contains four and hence binds the metal ions more stably
resulting in reduced ion leaching (Hochuli, E., et al. 1987, Block, H., et al. 2009). In this
project, the nickel-hexahistidine coordination is utilized for adsorbing candidate
therapeutic proteins onto PLGA particles that are functionalized with nickel atoms attached
on the surface.

3.2.2. Materials and Methods

3.2.2.1. Materials

18:1 DOGS-NTA-Ni (Nickel salt,1057 Da) was purchased from Avanti Polar Lipids, Inc.
Poly (D, L-lactide-co-glycolide) (PLGA, 50:50, IV 1.0 dl/g, 150000 g/mol, overall PDI
1.5-2.0) was purchased from Polysciences, Inc. Polyvinyl alcohol (PVA, 86-89%
hydrolyzed, low molecular weight), Invitrogen NativePAGE 4-16% Bis-Tris gel (1.0 mm
x 10 well), Novex sharp protein standard, dichloromethane (DCM, 99.9%), bovine serum
albumin (BSA), Tris base, D-(+)-trehalose dihydrate, Pierce LAL chromogenic endotoxin
quantitation kit, Pierce BCA protein assay kit, endotoxin-free ultrapure water, and EMD
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Millipor Millex sterile syringe filters were purchased from Thermo Fisher Scientific.
Transforming growth factor-beta 1 human recombinant, His tag (His-TGF1) and Protein
G human recombinant, His tag (His-pG) were purchased from ProSpec. Imidazole was
purchased from Sigma-Aldrich. Green fluorescent protein with a polyhistide tag at the Nterminus, Aequorea victoria, recombinant (His-tagged GFP, 5 µg/tube) was purchased
from Sino Biological Inc. Papain, Carica papaya (activity>30,000 USP units/mg) was
purchased from MilliporeSigma.

3.2.2.2. PLGA-Ni Particle Preparation

PLGA-Ni particles were prepared by incorporating metal chelating lipid 18:1 DOGS-NTANi (Figure 3-3) into the PLGA matrix using the method of double-emulsion solvent
evaporation. Then, His-tagged proteins can be adsorbed onto the surface of PLGA-Ni
microparticles based on the chelation reaction between nickel and polyhistidine tag (Figure
2-1). Specifically, DCM was used as the organic phase and 1% PVA aqueous solution was
selected as the water phase. The aqueous solution of 1% PVA was prepared by stirring
with heating at 90 C overnight. Prior to emulsification, 90 mg PLGA50:50 were dissolved
in 2.4 ml DCM and combined with 0.6 ml 10 mg/ml DOGS-NTA-Ni in DCM, followed
by the addition of 20 ml 1% PVA aqueous solution to the organic phase. Homogenization
was performed at 25000 rpm for 5 min on ice. By magnetic stirring in hood for 4 h to
evaporate DCM, the residual of the organic solvent was removed.
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Figure 3-3. The chemical structure of 18:1 DOGS-NTA-Ni.

Particles were collected through centrifugation and then washed twice with 10 ml of
ultrapure water by centrifuging at 15k rcf, 4 C for 20 min. To protect the freeze-dried
material, lyoprotectants such as trehalose and sucrose are often added before lyophilization
(Fonte, P., et al. 2016). In this experiment, particles were re-suspended in 12 ml 2%
trehalose aqueous solution. Then, pre-freezing was performed by rotating the glassware
containing particle suspension in dry ice-acetone bath, where the temperature was as low
as around -77 C (Percy, J., Moody, C., Harwood, L, 1998). Pre-freezing is one of the most
essential steps of the freeze dry process because creating more surface during the prefreezing process can speed up lyophilization, provide a thinner crust on the top layer of the
sample, prevent breaking of the glassware, and allow greater heat transfer during
lyophilization (Tang, X. and M. J. Pikal, 2004). After lyophilization for 3 days, particles
were collected and stored in a glass vial wrapped with parafilm and foil, and then saved
inside a desiccator at 4 C. After complete lyophilization, the yield of PLGA-Ni particle
preparation experiment is 275 mg of white powder.

3.2.2.3. PLGA-Ni Particle Characterization

3.2.2.3.1. Characterize Particle Size and Zeta Potential of PLGA-Ni Particle
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The size and Zeta potential of PLGA-Ni particles were measured by the Malvern Zetasizer
Nano-S (Malvern Instruments, UK) using the method of dynamic light scattering (DLS)
(Stetefeld, J., et al. 2016). To begin with, a series of PLGA-Ni particle suspensions were
prepared to find the most suitable concentration for DLS measurements. First, 5 mg of
PLGA-Ni particles were washed with 1ml of ultrapure water to get rid of trehalose,
followed by re-suspending in 1 ml of ultrapure water. Next, this suspension was diluted
2X, 10X, 20X, 50X, and 100X to make particle suspensions with different concentrations.
Then, particle size was measured on different dilutions using DLS. The concentration at
which both the attenuation and number of runs were ideal was selected for the following
tests. Accordingly, both particle size and Zeta potential of PLGA-Ni particles were then
measured at this concentration.

3.2.2.3.2. Characterize the Morphology of PLGA-Ni Particle

Scanning electron microscope (SEM) was used to characterize the morphology of PLGANi particles. To compare the difference between plain PLGA-Ni particles and PLGA-Ni
particles with proteins loaded, 5 mg of PLGA-Ni particles were washed and incubated with
His-TGFb for 1 h while another 5 mg of PLGA-Ni particles were not incubated with HisTGFb. Pellets were then centrifuged down at 13600 rcf, 4 C for 20 min and transferred to
eppendorf tubes on a rack, covering with aluminum film. A needle was used to punch small
holes on the film to ensure the particles inside can be dried effectively. The rack was placed
in a desiccator overnight. On the second day, the dried pellets were transferred to PELCO
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tabs (12 mm OD) and loaded onto SEM instrument for imaging. The mode selected is
variable pressure (VP) SEM with following setups: 5 kV of electron beam; probe current:
60; fast imaging mode for VP mode.

3.2.2.3.3. Characterize the Viscosity of PLGA-Ni Particle Suspension

The viscosity of PLGA-Ni particle suspension was measured for different particle
concentrations, i.e., 5 mg/ml, 10 mg/ml and 20 mg/ml. To make 500 µl of each particle
suspensions for the microVISC multi shear rates measurement, 5 mg, 10 mg, 20 mg of
PLGA-Ni particles are weighed out, washed with 1 ml of ultrapure water by centrifuging
at 4 °C, 16000 rcf for 10 min, followed by re-suspending in 500 µl of PBS, respectively.

Viscometer measurements were performed using the advanced settings: measurements
volume: Auto; priming volume: Auto; pausing time: 5 seconds; Temperature: 25 ºC; shear
rates: 8000 s-1, 6000 s-1, 4000 s-1, 3000 s-1, 2000 s-1, 1000 s-1. Measurements were
conducted from high shear rates to low shear rates. Water was included as the control.

3.2.2.3.4. Determine the Endotoxin Level in PLGA-Ni Particles

By testing the endotoxin standard solutions, an endotoxin standard curve was established.
Then, PLGA-Ni suspensions were measured on a microplate absorbance reader at 405 nm
within about 30 minutes. Finally, the endotoxin concentrations of the samples, in this case
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PLGA-Ni suspensions, were calculated based on the linear regression equation from the
standard curve.

3.2.2.4. Loading of His-tagged Proteins on PLGA-Ni Particles

3.2.2.4.1. Determine the Optimal Imidazole Concentration for Eluting Proteins

By taking advantage of the interaction between polyhistidine tag and the imidazole ring,
imidazole solution was used to elute the His-tagged proteins adsorbed on PLGA-Ni
particles. To optimize the concentration of imidazole for measuring the loading efficiency
of His-TGFb on PLGA-Ni particles, the effect of variation in imidazole concentration on
its ability to compete with polyhistidine tags in binding PLGA-Ni particles was tested.
Different imidazole aqueous solutions with concentrations including 0 mM, 10 mM, 25
mM, 50 mM, 75 mM, 100 mM, 150 mM, and 200 mM were prepared. For each imidazole
concentration, 5 mg of PLGA-Ni particles were washed and incubated with 250 µl of 0.02
µg/µl His-GFP and 250 µl imidazole solution of the specific concentration for 1 h at room
temperature. Tris buffer and His-GFP stock solution were included as the blank and the
control. After centrifuging and washing each pellet with cold Tris pH 8 buffer. Each
supernatant and pellet were saved and measured by plate reader. The excitation wavelength
and emission wavelength of His-tagged GFP are 487 nm and 508 nm, respectively.
Therefore, plate reader was used in the final step to detect the fluorescence intensity from
GFP by scanning the wells at 508 nm.
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3.2.2.4.2. Determine the Optimal pH Value for Tris Buffer to Eluting Proteins

Previous studies showed that the reaction between nickel atom and polyhistidine tag is
dependent on the pH of the environment (Bornhorst, J. A. and J. J. Falke, 2000, Nieba, L.,
et al. 1997). To achieve desired efficiency of eluting proteins adsorbed, different pH values
were test and the optimal pH was determined.

Tris buffers with different pH values were made by dissolving tris base in ultrapure water,
followed by adjusting pH with HCl and NaOH. Because pH lower than 6 or higher than 9
is likely to denature protein, pH 6, pH 7 and pH 8 were selected for the test. For each
concentration, 5 mg of PLGA-Ni particles were washed and re-suspended in 250 µl Tris
buffer of the concentration being tested. Next, His-GFP was loaded on PLGA-Ni particles.
First, 5 µg of His-GFP was reconstituted in 250 µl Tris buffer of the concentration being
tested, and then added to the particle suspension immediately. All samples were incubated
for 1 h at room temperature. Pellets were centrifuged down and washed with cold Tris
buffer. Both the supernatants and pellets were analyzed by testing the fluorescence
intensity from GFP using plate reader.

3.2.2.4.3. Loading Efficiency of His-tagged Proteins on PLGA-Ni Particles

Loading efficiency of His-TGFb on the surface of PLGA-Ni particles was measured by the
bicinchoninic acid assay (BCA assay), which is a biochemical assay for determining the
concentration of protein in a solution. The total protein concentration is exhibited by a color
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change of the sample solution from green to purple, which is in proportion to protein
concentration and can be measured using colorimetric techniques. The BCA assay
primarily relies on two reactions. First, the peptide bonds in protein reduce Cu2+ ions to
Cu+. The amount of Cu2+ reduced is proportional to the amount of protein in the sample
solution. Second, two molecules of bicinchoninic acid chelate with each Cu+ ion, forming
a purple-colored complex that strongly absorbs light at a specific wavelength around 540590 nm (Smith, P.K., et al. 1985).

According to the previous experiments, pH 8 Tris buffer and imidazole aqueous solution
with concentration of 200 mM were chosen for loading and eluting His-tagged proteins on
PLGA-Ni particles, respectively. In order to remove trehalose, 5 mg PLGA-Ni particles
were first washed with PBS solution 3 times before being added to 0.5 ml pH 8 Tris buffer.
Then, PLGA-Ni particle suspension was combined with 50 µl 0.07 µg/µl His-TGFb
aqueous solution. Samples were incubated for 1 h at room temperature to allow His-TGFb
to interact with PLGA-Ni particles. However, not all His-TGFb molecules adsorbed on the
surface of PLGA-Ni particles were caused by the specific binding between nickel and Histag. Thus, pellets were centrifuged and washed 3 times with cold pH 8 Tris buffer to get
rid of unspecific binding. Imidazole solution was then used to elute the remaining HisTGFb on PLGA-Ni particles; i.e., the pellets were re-suspended in the mixture of 0.5 ml
pH 8 Tris buffer and 0.5 ml 200 mM of imidazole aqueous solution and incubated for 0.5
h at room temperature. The supernatant from elution contains His-TGFb that was
successfully loaded onto the surface of PLGA-Ni particles through Ni-polyhistidine tag
interaction.
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Next, BCA assay was performed using diluted BSA standard (2.5-40 µg/ml) as standards,
PBS solution as blank, and the supernatants saved from elution as samples. The BCA
working reagent (Pierce BCA Reagent A (MA): Pierce BCA Reagent B (MB): Pierce BCA
Reagent C (MC) = 25: 24: 1) was prepared by mixing 2.5 ml MA, 2.4 ml MB and 0.1 ml
MC. To mix samples with the working reagent, 150 µl sample including BSA standard was
added to 96 well plate, and then 150 µl working reagent was added to each sample. The
microplate was well mixed and incubated for 2 h at 37 °C after sealing. After cooling the
plate to room temperature, the absorbance at 595 nm of each well in the microplate was
measured on a plate reader.

A standard curve was then established by plotting the average blank-corrected 595 nm
measurement for each BSA standard vs. its concentration. The standard solutions used have
following concentrations: 1.25 µg/ml, 2.5 µg/ml, 5 µg/ml, 10 µg/ml, 20 µg/ml, 40 µg/ml,
and 80 µg/ml. Finally, the protein concentration of each unknown sample was determined
based on the standard curve and the linear equation.

3.2.2.4.4. Identify the Protein Adsorbed on PLGA-Ni Particles

Although the BCA assay result suggests that proteins were detected in the supernatants
collected from eluting the PLGA-Ni particles incubated with His-TGFb, there is no direct
evidence proving the identity of these proteins. Thus, sodium dodecyl sulfate
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polyacrylamide gel (SDS-PAGE) electrophoresis was used to examine the molecular
weight of the proteins adsorbed on PLGA-Ni particles after the loading experiment.

SDS-PAGE electrophoresis is an electrophoretic technique widely used in biotechnology,
biochemistry, and other life science laboratories. In SDS-PAGE, proteins are separated in
a palyacrylamide gel based on their molecular weight. Proteins have both positive and
negative charges. To make proteins move in a single direction, a uniform negative charge
is created on them. Sodium dodecyl sulfate (SDS) is a detergent having a negative charge,
therefore it denatures the native proteins by disturbing the non-covalent forces (Saraswathy,
N. and Ramalingam, P., 2011). SDS also gives a uniform net negative charge to the protein
molecules. The denatured linear protein molecules are loaded onto the polyacrylamide gel
(PAGE) which is made by polymerizing the acrylamide monomers. PAGE has two phases:
a stacking gel and a separating gel. Under an applied electric field, the stacking gel
concentrates the SDS-loaded linear protein molecules while the separating gel separates
the proteins on the basis of molecular weight (Delves, P., 1998). After the run, PAGE gel
is stained to visualize the separated protein molecules as bands.

To prepare molecular weight marker, Novex Sharp protein standard was diluted by mixing
5 µl protein standard with 10 µl sample buffer and 25 µl PBS solution. Duplicates of
PLGA-Ni particles suspension saved after the incubation with His-TGFb in the loading
experiment were tested. Samples were prepared by mixing 5 µl sample buffer and 10 µl
PBS solution with 5 µl PLGA-Ni suspension, followed by heating at 70 °C for 10 min
before loading. The solution of molecular weight marker was kept at room temperature.
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Prior to running the electrophoresis under 200 V for 35 min, 20 µl of each sample and
molecular weight marker were loaded onto the wells in SDS-PAGE gel. The SDS-PAGE
gel was then stained through silver staining.

3.2.2.5. In Vitro Release of His-tagged Protein from PLGA-Ni Particles

3.2.2.5.1. In Vitro Release of His-GFP from PLGA-Ni Particles

The study of protein drug release in PLGA-Ni microparticles was performed with His-GFP
first. Specifically, 5 mg of PLGA-Ni particles were washed and resuspend in 100 µl of pH
8 Tris buffer. Particle suspension was then added to 200 µl of 0.025 µg/µl His-GFP to 0.2
ml pH 8 Tris buffer (0.5 ml Tris buffer in total), followed by incubation at room
temperature for 1 h. Then, pellets were centrifuged down by spinning at 13600 rcf, 4 C
for 20 min. To remove unspecific binding, each pellets was washed for another 3 times
with 0.5 ml of cold pH 8 Tris buffer prior to re-suspending in 1 ml of release medium,
which was then transferred into a 1 ml syringe. Syringes were then incubated at 37 ºC to
mimic the release condition in vivo. The release medium in this experiment is 0.1% bovine
serum albumin (BSA) in PBS solution, considering the fact that BSA can reduce the
adsorption of proteins on the walls of containers (Goebel-Stengel, M, et al. 2011). Syringes
were used with 0.22 µm syringe filters attached to trap the PLGA-Ni particles during
dispensing.
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In order to monitor the release of His-GFP from PLGA-Ni particles in the release medium,
samples were drawn everyday from Day 1 to Day 14. On Day 1, i.e. the first day of release,
100 µl of solution was dispensed through the 0.2 µm filter on the syringe after 1 h, 2 h, 3
h, 4 h and 5 h of incubation at 37 ºC. Each dispensing was followed by replenishing the
syringe with another 100 µl release medium. From Day 2 to Day 14, 100 µl of solution was
dispensed through the syringe filter at the same time as the last time point on Day 1. Every
time a sample was collected, the syringe was replenished with 100 µl of release medium.
The fluorescence intensity of every sample was measured by plate reader at 508 nm, which
reflects the amount of His-GFP contained in each release sample.

A standard curve was established for subsequent quantification of the release samples. The
concentrations of His-GFP standards include 0.0098 µg/ml, 0.0195 µg/ml, 0.0391 µg/ml,
0.0781 µg/ml, 0.1563 µg/ml, 0.3125 µg/ml, 0.625 µg/ml, 1.25 µg/ml, and 2.5 µg/ml. The
fluorescence intensity from GFP in each His-GFP standard is measured by plate reader at
508 nm with gain value of 255, which is in consistent with the gain used for the release
study. The release of His-GFP was then quantified by calculating the cumulative released
percentage based on the standard curve.

3.2.2.5.2. In Vitro Release of His-TGFb from PLGA-Ni Particles

Not only His-GFP, His-TGFb was also used for the release study. Specifically, 5 mg of
PLGA-Ni particles were washed and resuspend in 100 µl of pH 8 Tris buffer. Particle
suspension was then added to 61 µl of 0.164 µg/µl His-TGFb to 339 µl Tris pH 8 buffer
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(0.5 ml Tris buffer in total), followed by incubation at room temperature for 1 h. Then,
pellets were centrifuged down by spinning at 13600 rcf, 4 C for 20 min. To remove
unspecific binding, each pellets was washed for another 3 times with 0.5 ml of cold pH 8
Tris buffer prior to re-suspending in 1 ml of release medium, which was then transferred
into a 1 ml syringe. Then, syringes were incubated at 37 ºC to mimic the release condition
in vivo. The release medium in this experiment is also 0.1% BSA in PBS solution. Syringes
were attached with 0.22 µm syringe filters to trap the PLGA-Ni particles during dispensing.

Release samples were collected using the same method described above and studied by
conducting SDS-PAGE electrophoresis.

3.2.2.6. Enzymatic Degradation of Protein Absorbed on PLGA-Ni
Particles

PLGA-Ni particles are expected to not only be able to bind His-tagged proteins on the
surface, but also have a protective effect for protein drugs. To test whether adsorbed
proteins are protected from enzymatic degradation by PLGA-Ni particles, papain was
selected to evaluate the enzyme effect on proteins adsorbed or not adsorbed onto PLGANi particles.

To achieve this purpose, PLGA-Ni particle were first loaded with His-tagged protein G
(His-pG) as following: 10 mg of PLGA-Ni particles were washed and re-suspended in 470
µl pH8 Tris buffer with 30 µl of 10 µg/µl His-pG stock solution added, followed by
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incubation for 1 h at room temperature. In order to reveal the impact of enzyme
concentration on the rate of protein degradation, two papain concentrations were used in
this experiment: high enzyme concentration with a ratio of 10 U of papain activity per
microgram of His-pG for the first experiment group (Exp. 1), and low enzyme
concentration with a ratio of 2 U of papain activity per microgram of His-pG for the second
experiment group (Exp. 2). Specifically, 3000 U of papain was added to the particle
suspension after loading in Exp. 1 while 600 U of papain was added in Exp. 2. The controls
did not include PLGA-Ni particles, in order to show the effect of papain on proteins not
adsorbed on particles. There are four groups of control, i.e., the first control group (Control
1) tested the influence of high enzyme concentration on His-pG, the second control group
(Control 2) tested the influence of low enzyme concentration on His-pG, the third control
group (Control 3) tested the change in His-pG when no enzyme was added, and the fourth
control group (Control 3) only included papain and Tris bufer. More details were provided
in Table 3-1.

Table 3-1. Sample order of papain degradation experiment.
PLGA-Ni (mg)

Tris buffer (µl)

His-pG (µl)

papain (U/ml)

Exp 1

10

470

30

30000

Exp 2

10

470

30

6000

Control 1

0

470

30

30000

Control 2

0

470

30

6000

Control 3

0

470

30

0

Control 4

0

470

0

30000
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All samples were incubated at 37 ºC with sampling at 30 min, 4h, 18h (overnight) by
centrifuging and collecting the supernatants. Then, the supernatants saved were used for
SDS-PAGE electrophoresis via silver staining (Figure 2-23). The protein G His Tag
recombinant used is produced in E. coli with 201 amino acids and a C-terminal 6-His tag,
having a molecular mass of 21.6 kDa. But it should be pointed out that His-pG migrates
with an apparent molecular mass of 32 kDa in SDS-PAGE.

3.2.3. Results

3.2.3.1. PLGA-Ni Particle Characterization

3.2.3.1.1. Characterize Particle Size and Zeta Potential of PLGA-Ni Particle

As showed in Figure 3-4, when PLGA-Ni microparticles were not loaded with His-TGFb,
particle size was 867.5 nm (PDI 0.183). But when His-TGFb was loaded, particle size
increased to 1088.6 nm (PDI 0.168). These measurements showed that the size of the
PLGA-Ni particles prepared using the method described above is in the range of
microparticles. Additionally, the low PDI values indicate that PLGA-Ni particles have a
good uniformity, no matter His-TGFb was adsorbed or not.
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Figure 3-4. Particle size distribution of PLGA-Ni particles with and without His-TGFb
loaded (the concentration of PLGA-Ni is 2.5 mg/ml in pH 7 PBS solution with ionic
strength of 162.7 mM).

On the other hand, Zeta potential of plane PLGA-Ni particle was around -29.37±0.153 mV
without His-TGFb (Figure 3-5). But PLGA-Ni particle with His-TGFb loaded has a Zeta
potential of 0.44 mV. This result suggested that loading His-TGFb onto PLGA-Ni particles
disturbs the colloidal stability of the particles. The reason for this change in Zeta potential
is that the negative charges on PLGA-Ni particles was neutralized after the loading of HisTGFb. Therefore, the decrease in Zeta Potential indicates the adsorption of His-TGFb on
the surface of PLGA-Ni particles.
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Figure 3-5. Zeta potential of PLGA-Ni particles with and without His-TGFb loaded (the
concentration of PLGA-Ni is 2.5 mg/ml in de-ionized water).

3.2.3.1.2. Characterize the Morphology of PLGA-Ni Particle

The SEM images demonstrated that PLGA-Ni particles have spherical shape as expected
(Figure 3-6). The plain PLGA-Ni particles tend to be individual spheres under SEM
scanning, but the His-TGFb adsorbed PLGA-Ni particles formed clumps because of
aggregation.

95

(a)

(b)

Figure 3-6. Particle morphology of PLGA-Ni particles: (a) without His-TGFb loaded, (b)
with His-TGFb adsorbed.

There are two main reasons for the aggregation in protein adsorbed PLGA-Ni particles.
First, the electrostatic repulsive forces between particles were reduced due to the adsorption
of protein on particle surface, which is confirmed by the decrease noticed in electronegative
zeta potential values when comparing plain PLGA-Ni particles with PLGA-Ni particles
loaded with His-TGFb. In addition, it is possible that the amount of protein added was high
enough that protein molecules on particle surface were likely to aggregate with the proteins
adsorbed on another particle, resulting in large clusters in the SEM image (Figure 3-6, b).
Thus, incubating less His-tagged proteins with PLGA-Ni particles should reduce this
aggregation in the loading process.

3.2.3.1.3. Characterize the Viscosity of PLGA-Ni Particle Suspension
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It is showed in Figure 3-7 that the viscosity of PLGA-Ni particle suspension increases as
particle concentration increases. When the concentration is lower than 5 mg/ml, the
viscosity of PLGA-Ni particle suspension is close to water. Moreover, the viscosity of
particle suspension did not increase significantly when the concentration changes from 5
mg/ml to 10 mg/ml. This result suggests that in experiments where the concentration of
PLGA-Ni suspension is in the range of 0-10 mg/ml, the influence of viscosity on particle
performance is negligible. In the following experiments, the concentration of the PLGANi suspensions used did not exceed 5 mg/ml.

Figure 3-7. Viscosity of PLGA-Ni particle suspension under different shear rate.

3.2.3.1.4. Determine the Endotoxin Level in PLGA-Ni Particles

As showed in Figure 2-12, endotoxin standard curve has been established and the linear
regression equation was y = 3.2435x - 0.2669, R2=0.9724. The measurement of PLGA-Ni
suspensions showed that endotoxin concentration of PLGA-Ni particles was 1.01 EU/ml
or 0.202 EU/mg, which basically meets the 0.1-1.0 EU/ml range. According to this
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endotoxin level, the dose of PLGA-Ni particles for animal study in preclinical evaluation
can be calculated using the USP recommended endotoxin limit of 5 EU/kg.

3.2.3.2. Loading of His-tagged Proteins on PLGA-Ni Particles

3.2.3.2.1. Determine the Optimal Imidazole Concentration for Eluting Proteins

In Figure 3-8, preliminary results showed that the concentration of His-GFP in supernatants
increases as imidazole concentration increases. In contrast, the percentage of His-GFP
retained in PLGA-Ni pellets decreases when imidazole concentration increases (Figure 39). Therefore, among the imidazole concentrations tested, 200 mM of imidazole aqueous
solution is selected for eluting the adsorbed His-tagged protein effectively and determining

Protein released in sup (%)

the loading efficiency of protein drugs on PLGA-Ni particles.

100.00
80.00
60.00
40.00
20.00
0.00
0

100

200

300

imidazole concentration (mM)

Figure 3-8. Preliminary results on the change in the percentage of His-GFP released in
supernatant with varying imidazole concentrations (error bars are not included since this is
a titration experiment that is not repeated yet).
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Figure 3-9. Preliminary results on the change in the percentage of His-GFP retained in
pellet with varying imidazole concentrations (error bars are not included since this is a
titration experiment that is not repeated yet).

3.2.3.2.2. Determine the Optimal pH Value for Tris Buffer to Eluting Proteins

From the preliminary results on the percentage of His-GFP released in the supernatants and
retained in the pellets (Figure 3-10 and Figure 3-11), pH 8 Tris buffer demonstrated the
strongest ability in eluting proteins adsorbed on PLGA-Ni particles. This result is due to
the fact that the imidazole rings in polyhistidine tag are less likely to be protonated under
weakly alkaline condition. Based on these comparisons, pH 8 Tris buffer is considered as
the optimal pH environment for the adsorbed proteins to be released from PLGA-Ni
particles.
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Figure 3-10. Preliminary results on the percentage of His-GFP released in supernatants at
different pH (error bars are not included since this is a titration experiment that is not
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Figure 3-11. Preliminary results on the percentage of His-GFP retained in pellets at
different pH (error bars are not included since this is a titration experiment that is not
repeated yet).
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3.2.3.2.3. Loading Efficiency of His-tagged Proteins on PLGA-Ni Particles

Based on the standard curve y = 0.0066x + 0.0003 (R2=0.9981), the protein concentration
of each unknown sample was determined (Figure 3-12). According to the readout of plate
scanning, the average concentration of protein in samples is 1.567 µg/µl. Therefore, on
average 1.567 µg of His-TGFb was eluted by imidazole after incubating PLGA-Ni particles
with 3.445 µg of His-TGFb in pH 8 Tris buffer. Accordingly, around 45.52% of the initial
loading amount of His-TGFb was adsorbed onto PLGA-Ni particles through Nipolyhistidine tag interaction.

Figure 3-12. Standard curve for BCA assay.

3.2.3.2.4. Identify the Protein Adsorbed on PLGA-Ni Particles

The result from SDS-PAGE electrophoresis is showed in Fig 3-13. The first lane on the
right is loaded with molecular weight marker. The two lanes on the left are both PLGA-Ni
particles saved after incubating with His-TGFb and imidazole in the previous experiment,
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which showed a band at 20 kDa. This result indicates that a protein with molecular weight
of 20 kDa was adsorbed on PLGA-Ni particles. According to the molecular weight of HisTGFb (21.8 kDa), this band should be denatured His-TGFb, suggesting that His-TGFb was
successfully adsorbed onto PLGA-Ni particles via specific binding.

Figure 3-13. SDS-PAGE electrophoresis result after loading His-TGFb onto PLGA-Ni
particles (The first two lanes on the left: duplicates of PLGA-Ni particles incubated with
His-TGFb; The first lane on the right: molecular weight marker).

3.2.3.3. In Vitro Release of His-tagged Protein from PLGA-Ni Particles

3.2.3.3.1. In Vitro Release of His-GFP from PLGA-Ni Particles

The standard curve (Figure 3-14) showing the relationship between the concentration of
His-GFP and the fluorescence intensity from GFP was depicted as the following with a
linear equation of y = 11803x + 4528.9 (R2 = 0.9965).
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Figure 3-14. Standard curve for the fluorescence intensity of His-GFP.

The result showed in Figure 3-15 illustrated that the release of His-GFP was sustained for
8 days. More than 80% of His-GFP loaded was released from PLGA-Ni particles during
the first week of release. Compared to the solution of His-GFP, the release of His-GFP was
prolonged when PLGA-Ni particle was used to deliver the protein. This result suggests that
PLGA-Ni particle is a viable carrier for delivering His-tagged proteins and sustaining the
release rate.

Figure 3-15. Release of His-GFP from PLGA-Ni particles from Day 1 to Day 8 in PBS at
37 C (n=3, the excitation/emission wavelength of GFP is 487 nm/508 nm).
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Compared to the release profile of desthiobiotinylated drug adsorbed on PLGA-biotin
particles, His-tagged proteins showed a faster release from PLGA-Ni particles. The main
reason for this difference is that the dissociation constant (Kd) for the interaction between
avidin and biotin is 10-15, which indicates that the binding between avidin and biotin is
much stronger than the interaction between Ni and polyhistidine tag where Kd is 10-6 in the
pH 7 release medium (Bornhorst, J. A. and J. J. Falke 2000). Therefore, avidin-bound drug
takes a longer time to be dissociated and released from PLGA-biotin than His-tagged
proteins adsorbed on PLGA-Ni if biotin is not presented in the release medium.

3.2.3.4. Enzymatic Degradation of Protein Absorbed on PLGA-Ni
Particles

Papain was used to probe the extent to which proteins adsorbed on PLGA-Ni could be
digested. In the electrophoresis result (Figure 3-16), lane 9 indicates the band of pure HispG is around 30 kDa. When the concentration of papain was high (30000 U/ml), both
PLGA-adsorbed His-pG and plain His-pG were degraded to a large extent and no specific
band showed up around 30 kDa. But when the papain concentration was relatively low
(6000 U/ml), PLGA-adsorbed His-pG (lane 2) showed a much stronger band around 30
kDa than His-pG alone (lane 4). This result suggests that PLGA-Ni particle has the ability
to protect surface-adsorbed protein against low concentration of enzyme. But high
concentration of enzyme could still damage the proteins absorbed.
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Figure 3-16. SDS-PAGE electrophoresis result of His-pG degradation with and without
being absorbed on PLGA-Ni particles. Sample order: lane 1-30 min after incubating
PLGA-absorbed His-pG with 30000 U/ml papain, lane 2-30 min after incubating PLGAabsorbed His-pG with 6000 U/ml papain, lane 3-30 min after incubating His-pG with
30000 U/ml papain, lane 4-30 min after incubating His-pG with 6000 U/ml papain, lane 54 h after incubating PLGA-absorbed His-pG with 30000 U/ml papain, lane 6-4 h after
incubating PLGA-absorbed His-pG with 6000 U/ml papain, lane 7-4 h after incubating
His-pG with 30000 U/ml papain, lane 8-4 h after incubating His-pG with 6000 U/ml papain,
lane 9-His-pG.

3.3. Incorporation of PLGA-Ni Particles into EAK Hydrogel

3.3.1. EAK16-II: self-assembling peptide

Considering the fact that the biological drugs adsorbed on the surface of PLGA-Ni have
the potential to be denatured by proteases and other factors in the environment or under
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physiological conditions in vivo, EAK16-II hydrogel will be used to incorporate the drug
loaded PLGA-biotin particles in future studies since the network of EAK16-II gel is
resistant to acids and proteases and can work as the barrier against protein denaturation.

EAK16-II is a self-assembling amphiphilic peptide, consisting of alternating hydrophobic
(A) and hydrophilic (E and K) amino acids (amino acid sequence: AEAEAKAK) (Zhang,
S., et al. 1993). Through ionic complementary interactions between the residues with
periodic negative and positive charges, EAK16-II spontaneously undergoes -fibrillizition
when exposed to high ionic strength (20 mM) (Wen, Y., et al. 2014). Subsequent crosslinking of these self-assembled nanofibers leads to insoluble quaternary -structures, which
are resistant to acids and proteases (Zhang, S., et al. 1994). Dissociated biological drugs
may bind to these fibrils, further delaying their release into the environment. The density
of EAK16-II concentration can alter the stability of the released protein. However, dense
network may also impede the diffusion of particles to the extent that they are virtually
immobilized.

Figure 3-17. The formation of EAK16-II fibrous network through self-assembling and fibrillizition.
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Loading protein on the surface of microparticles, however, can destabilize the colloidal
stability. This can be addressed by embedding the particles in the EAK16-II gel, in which
the fibriller matrix serves as a barrier against particle aggregation and protein denaturation.
Therefore, EAK16-II gel is believed to be able to work as a second barrier against chemical
and physical reagents in environment or serum that may cause protein degradation. An
ideal particle-EAK16-II system should have reasonably high loading efficiency, reduced
burst release effect, sustained release profile and retained bioactivity. Thus, it is necessary
to find out the optimal EAK16-II density for incorporating particles. The following
experiments were the preliminary studies on the incorporation of PLGA-Ni particles in
EAK16-II hydrogel, in order to provide a basis for the further research on the optimal
formulation of EAK16-II hydrogel and PLGA-Ni particles in the future.

3.3.2. Materials

EAK16-II was custom synthesized by American Peptide Company (Sunnyvale, CA) at
greater than 95% purity with the N-terminus acetylated and C-terminus amidated. Green
fluorescent protein with a polyhistide tag at the N-terminus, Aequorea victoria,
recombinant (His-tagged GFP, 5 µg/tube) was purchased from Sino Biological Inc.
Slowfade Diamond anti-fade mounting solution (2 ml in total) was purchased from Thermo
Fisher Scientific.

3.3.3. Method and Result
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In the preliminary studies, a high concentration of EAK16-II, 5 mg/ml was used for gel
formation. However, in contrast to individual spheres when not incorporated (Figure 3-18),
the particles became aggregates and attached to gel matrix after incorporated into EAK16II gel as showed in the microscopic images in Figure 3-19. This might be due to the high
viscosity of EAK16-II gel formed, which results in uneven distribution of the particles. It
is important to adjust the concentration of EAK16-II and consequently the viscosity of
EAK16-II gel to reduce this aggregation and ensure the protein drug is not denatured after
being incorporated into the hydrogel.

Figure 3-18. Microscopic image of PLGA-Ni particle loaded with His-GFP.

Figure 3-19. Microscopic image of PLGA-Ni particle loaded with His-GFP in EAK16-II
gel.
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3.4. Dual Delivery of ATRA and TGF-beta 1 through PLGA-Ni Particles

3.4.1. All-trans Retinoic Acid (ATRA)

Not only biological drugs such as His-tagged proteins can be loaded onto PLGA-Ni
particles through surface adsorption, but small molecules can also be delivered by PLGANi particles. In this project, all-trans retinoic acid, or ATRA, was encapsulated into the
polymer matrix of PLGA-Ni particles to enhance the drug efficiency of the macromolecule
drug, which in this case is TGF-beta 1, that was adsorbed on the surface of PLGA-Ni.

All-trans retinoic acid (ATRA), also known as tretinoin, has been reported to be able to
improve the drug effect of TGF-beta 1 by synergizing in suppressing inflammation. The
chemical structure of ATRA is demonstrated in Figure 3-20.

Figure 3-20. The chemical structure of ATRA.

According to the literature, ATRA and TGF-beta 1 induce CD4 cells (Schiavinato, J., et al.
2017), a type of islet antigen-specific T cells, to develop into regulatory T cells (Figure 321). Subsequently, the amount of CD4 cells differentiated into T helper 17 cells will be
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reduced. T helper 17 (Th17) cells are a subset of pro-inflammatory T helper cells and have
been implicated in autoimmune and inflammatory disorders. Therefore, ATRA is believed
to be promising in assisting TGF-beta 1 to reduce inflammation. In order to achieve a better
drug efficiency, dual loading of TGF-beta 1 and ATRA on PLGA-Ni particles is considered
as one of the future research directions of studying PLGA-Ni particles.

Figure 3-21. ATRA synergizes with TGF-beta 1 in suppressing inflammation.

3.4.2. Materials

All-trans retinoic acid (ATRA), powder, ≥98% (HPLC) was purchased from SigmaAldrich. 18:1 DOGS-NTA-Ni (Nickel salt,1057 Da) was purchased from Avanti Polar
Lipids, Inc. Poly (D, L-lactide-co-glycolide) (PLGA, 50:50, IV 1.0 dl/g) was purchased
from Polysciences, Inc. Polyvinyl alcohol (PVA, 86-89% hydrolyzed, low molecular
weight), dichloromethane (DCM, 99.9%) and D-(+)-trehalose dihydrate were purchased
from Thermo Fisher Scientific.
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3.4.3. Method and Results

First, PLGA (ATRA)-Ni particles was prepared using the method of double-emulsion
solvent evaporation as following. DCM was used as the organic phase and 1% PVA
aqueous solution was selected as the water phase. The aqueous solution of 1% PVA was
prepared by stirring with heating at 90 C overnight. Prior to emulsification, 90 mg
PLGA50:50 and 5 mg ATRA were dissolved in 2.4 ml DCM and combined with 0.6 ml 10
mg/ml of the metal chelating lipid DOGS-NTA-Ni in DCM, followed by the addition of
20 ml 1% PVA aqueous solution to the organic phase. Theoretically, 0.57 µmol nickel
should be incorporated in the particles. Homogenization was performed at 25000 rpm for
5 min on ice. By magnetic stirring in hood for 4 h to evaporate DCM, the residual of the
organic solvent was removed. Particles were collected through centrifugation and then
washed twice with 10 ml of ultrapure water by centrifuging at 15k rcf, 4 C for 20 min. To
protect the freeze-dried material, particles were re-suspended in 12 ml 2% trehalose
aqueous solution. Then, pre-freezing was performed by rotating the glassware containing
particle suspension in dry ice-acetone bath. After lyophilization for 3 days, particles were
collected and stored in a glass vial wrapped with parafilm and foil, and then saved inside a
desiccator at 4 C. Finally, the yield of this PLGA (ATRA)-Ni particle preparation is 300
mg of yellow particles.

To determine the drug content of ATRA in PLGA (ATRA)-Ni particles, UV absorbance
of PLGA (ATRA)-Ni particle sample dissolved in DCM was measured at 366 nm.
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According to the UV absorbance of standard ATRA solution, drug content of ATRA in
prepared particles was calculated to be 4.42 µg/mg and the loading efficiency of ATRA
was calculated as 26.51%.

Moreover, to verify the purity of ATRA we load in particles and to establish a method for
quantifying the release of ATRA, the method of HPLC was utilized. Figure 3-22 showed
the standard curve of ATRA using HPLC, according to which the amount of ATRA in the
release samples can be determined.

Figure 3-22. HPLC standard curve for ATRA.

Figure 3-23 shows the HPLC analysis result of the ATRA solution used for preparing
PLGA (ATRA)-Ni particles, which is in consistency with the expected HPLC result for
pure ATRA in literatures (Agadir, A., et al. 1995). This result suggests that the ATRA
solution used for PLGA (ATRA)-Ni particles has a high level of purity.
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Figure 3-23. HPLC analysis result for ATRA standard solution.

3.5. Future Work on PLGA-biotin Particles

The polydispersity index and average Zeta potential of PLGA-biotin particles indicate that
the formulation variables and production process of PLGA-biotin needs to be optimized to
improve the homogeneity and stability of PLGA-biotin. In addition, in order to stabilize
the colloidal suspension of PLGA-biotin, two main mechanisms for stabilization against
aggregation should be taken into consideration, i.e., electrostatic stabilization and steric
stabilization.

Electrostatic stabilization is based on the mutual repulsion between electrical charges. In a
stable colloid suspension, mass of a dispersed phase is so low that its kinetic energy can
hardly overcome the electrostatic repulsion between the charged layers in the dispersing
phase (Jacob, I. 1991). Steric stabilization consists in covering the particles in polymers,
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which prevents the particles to get close in the range of attractive forces (Elimelech, M., et
al. 1998).
The role of ionic strength in promoting flocculation or stabilization of colloidal dispersions
is mainly determined by the predominant electrostatic interaction between particles (Zhang,
H., et al. 2007). The addition of salt also has the potential to weaken the particle–particle
and particle–interface repulsive electrostatic forces, which leads to destabilization of the
suspension (Bizmark, N. and M. A. Ioannidis, 2015). Therefore, the gel network
stabilization represents a better way to produce colloid suspension of PLGA-biotin
particles that is stable to both aggregation and sedimentation. In future studies, EAK16-II
self-assembling peptide could be used to form a hydrogel network that can stabilize PLGAbiotin particles in dispersions, because the long fibers in EAK16-II gel can provide a steric
stabilization to dispersed particles. Accordingly, the concentration of EAK16-II added in
PLGA-biotin suspension also needs to be optimized in future studies to ensure both a
decent stability and a desired release profile.
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